
Literatur

Kap. 1

- [1] Bettman JW. Seven hundred medicolegal cases in ophthalmology. *Ophthalmology* 1990; 97: 1379–1384
- [2] Brick DC. Medication errors result in costly claims for ophthalmologists. *Surv Ophthalmology* 1995; 40: 232–236
- [3] Davies EC, Green CF, Mottram DR et al. Adverse drug reactions in hospitals: a narrative review. *Curr Drug Saf* 2007; 2: 79–87
- [4] Egger SS, Schlienger RG, Krähenbühl S. Vorgehen bei unerwünschten Arzneimittelwirkungen. *Schweiz Med Forum* 2005; 5: 292–296
- [5] Fechner PU, Teichmann KD. *Medikamentöse Augentherapie*. 4. Aufl. Stuttgart: Enke im Georg Thieme Verlag; 2000: 3
- [6] Fraunfelder FT. Extraocular fluid dynamics: how best to apply topical ocular medication. *Trans Am Ophthalmol Soc* 1976; 74: 457–487
- [7] Jönsson AK, Spigset O, Tjäderborn M et al. Fatal drug poisonings in a Swedish general population. *BMC Clin Pharmacol* 2009a; 9: 7
- [8] Jönsson AK, Hakkarainen KM, Spigset O et al. Preventable drug related mortality in a Swedish population. *Pharmacoepidemiol Drug Saf* 2009b; 19: 211–215
- [9] Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears ML, ed. *Handbook of experimental pharmacology*. Vol. 69: *Pharmacology of the eye*. New York: Springer; 1984: 19–116
- [10] McMartin C, Hutchinson LE, Hyde R et al. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. *J Pharm Sci* 1987; 76: 535–540
- [11] Sackett DL, Rosenberg WM, Gray JA et al. Evidence based medicine: what it is and what it isn't. *BMJ* 1996; 312: 71–72
- [12] Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications. Recognition and management. *Drugs* 2007; 67: 75–93

Kap. 2

- [1] Albert DM, Wong VG, Henderson ES. Ocular complications of vincristine therapy. *Arch Ophthalmol* 1967; 78: 709–713
- [2] Alinovi A, Reverberi C, Melissari M et al. Cutaneous hyperpigmentation induced by amiodarone hydrochloride. *J Am Acad Dermatol* 1985; 12: 563–566 EBM K6
- [3] Allen JE. Drug-induced photosensitivity. *Clin Pharm* 1993; 12: 580–587
- [4] Asensio V, del Pozo LJ, Ansensio M et al. Megalotrichiasis and poliosis caused by cyclosporin A [Artikel in Spanisch]. *Med Clin (Barc)* 1991; 97: 39 EBM K6
- [5] Bambury R, McCaffrey JA. Trichomegaly of the eyelashes after colorectal cancer treatment with the epidermal growth factor receptor inhibitor cetuximab. *Clin Colorectal Cancer* 2009; 8: 235 EBM K6
- [6] Bay A, Yilmaz C, Yilmaz N et al. Vincristine induced cranial polyneuropathy. *Indian J Pediatr* 2006; 73: 531–533 EBM K6
- [7] Bearden W, Anderson R. Trichiasis associated with prostaglandin analog use. *Ophthal Plast Reconstr Surg* 2004; 20: 320–322 EBM K6
- [8] Berstein LP, Henkind P. Additional information on adverse reactions to timolol. *Am J Ophthalmol* 1981; 92: 295–296 EBM K6
- [9] Blackshear JL, Randle HW. Reversibility of blue-gray cutaneous discoloration from amiodarone. *Mayo Clin Proc* 1991; 66: 721–726 EBM K6
- [10] Borchard K, Puy R, Nixon R. Hyaluronidase allergy: a rare cause of periorbital inflammation. *Australas J Dermatol* 2010; 51: 49–51 EBM K6
- [11] Bozkurt B, Irkec MT, Atakan N et al. Lacrimal function and ocular complications in patients treated with systemic isotretinoin. *Eur J Ophthalmol* 2002; 12: 173–176 EBM K4
- [12] Centofanti M, Oddone F, Chimenti S et al. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy. *Am J Ophthalmol* 2006; 142: 1059–1060 EBM K2
- [13] Deluise VP, Flynn JT. Asymmetric anterior segment changes induced by chlorpromazine. *Ann Ophthalmol* 1981; 13:

-
- [14] Demitsu T, Manabe M, Harima N et al. Hypertrichosis induced by latanoprost. *J Am Acad Dermatol* 2001; 44: 721–723
- [15] Doshi M, Edward DP, Osmanovic S. Clinical course of bimatoprost-induced periocular skin changes in caucasians. *Ophthalmology* 2006; 113: 1961–1967 EBM K5
- [16] D'Ostroph AO, Dailey RA. Cicatricial entropion associated with chronic dipivefrin application. *Ophthal Plast Reconstr Surg* 2001; 17: 328–331 EBM K6
- [17] Drucker AP, Sadove MS, Unna KR. Ophthalmic studies of curare and curare-like drugs in man. *Am J Ophthalmol* 1951; 34: 543–553
- [18] Dutkiewicz R, Albert DM, Levin LA. Effect of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. *Exp Eye Res* 2000; 70: 563–569
- [19] Dyster-Aas K, Hansson H, Miörner G et al. Pigment deposits in eyes and light-exposed skin during long-term methacycline therapy. *Acta Derm Venerol* 1974; 54: 209–221 EBM K6
- [20] Eberhard AH, Weiler CR, Erie JC. Angioedema related to the use of hyaluronidase in cataract surgery. *Am J Ophthalmol* 2004; 138: 142–143 EBM K6
- [21] Egger SF, Huber-Sptzy V, Böhler K et al. Isotretinoin administration in treatment of acne vulgaris. A prospective study of the kind and extend of ocular complications. *Ophthalmology* 1995; 92: 17–20 EBM K4
- [22] Eisen D, Hakim MD. Minocycline-induced pigmentation. Incidence, prevention and management. *Drug Saf* 1998; 18: 431–440
- [23] Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. *Drugs* 1993; 45: 953–1040
- [24] Feibel RM, Custer PL, Gordon MO. Postcataract ptosis. A randomized, double-masked comparison of peribulbar and retrobulbar anesthesia. *Ophthalmology* 1993; 100: 660–665 EBM K1
- [25] Feletti F, Vincenzi C, Pazzaglia M et al. Periocular pigmentation associated with use of travoprost for the treatment of alopecia areata of the eyelashes. *J Eur Acad Dermatol Venereol* 2007; 21: 421–423 EBM K6
- [26] Foerster CG, Cursiefen C, Kruse FE. Persisting corneal erosion under cetuximab (Erbix) treatment (epidermal growth factor receptor antibody). *Cornea* 2008; 27: 612–614 EBM K6
- [27] Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. *Br J Ophthalmol* 1995; 79: 54–56 EBM K5
- [28] Fraunfelder FW, Solomon J, Druker BJ et al. Ocular side-effects associated with imatinib mesylate (Gleevec). *J Ocul Pharmacol Ther* 2003; 19: 371–375 EBM K5
- [29] Fraunfelder FW, Richards AB. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3methyl-glutaryl-CoA reductase inhibitor use. *Ophthalmology* 2008; 115: 2282–2285 EBM K5
- [30] Gadhia K, Walmsley AD. Facial aesthetics: is botulinum toxin treatment effective and safe? A systematic review of randomised controlled trials. *Br Dent J* 2009; 207: E9
- [31] Geria AN, Tajirian AL, Kihiczak G et al. Minocycline-induced skin pigmentation: an update. *Acta Dermatovenerol Croat* 2009; 17: 123–126
- [32] Gigantelli JW, Braddock SR, Johnson LN. Blepharoptosis and central nervous system abnormalities in combined valproate and hydantoin embryopathy. *Ophthal Plast Reconstr Surg* 2000; 16: 52–54 EBM K6
- [33] Grierson I, Jonsson M, Cracknell K. Latanoprost and pigmentation. *Jpn J Ophthalmol* 2004; 48: 602–612
- [34] Gursel O, Sari E, Altun D, Atay AA et al. Vincristine-induced unilateral ptosis in a child. *Pediatr Neurol* 2009; 41: 461–463 EBM K6
- [35] Imperia PS, Lazarus HM, Lass JH. Ocular complications of systemic cancer therapy. *Surv Ophthalmol* 1989; 34: 209–230
- [36] Jacob SE, Blyumin M. Vitiligo-like hypopigmentation with poliosis following treatment of superficial basal cell carcinoma with imiquimod. *Dermatol Surg* 2008; 34: 844–845 EBM K6
- [37] Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. *Am J Ophthalmol* 1997; 124: 544–547 EBM K4
- [38] Kanwar AJ, Dhar S, Ghosh S. Photosensitive lichenoid eruption due to enalapril. *Dermatology* 1993; 187: 80 EBM K6
- [39] Karalezli A, Borazan M, Altinors DD et al. Conjunctival impression cytology, ocular surface, and tear-film changes in patients treated with systemic isotretinoin. *Cornea* 2009; 28: 46–50 EBM K4

-
- [40] Kashiwagi K, Tsukamoto K, Suzuri M et al. Effects of isopropyl unoprostone and latanoprost on melanogenesis in mouse epidermal melanocytes. *J Glaucoma* 2002; 11: 57–64
- [41] Kincaid MC, Green WR, Hoover RE et al. Ocular chrysiasis. *Arch Ophthalmol* 1982; 100: 1791–1794 EBM K6
- [42] Kook MS, Lee K. Increased eyelid pigmentation associated with use of latanoprost. *Am J Ophthalmol* 2000; 129: 804–806 EBM K6
- [43] Lane K, Goldstein SM. Erlotinib-associated trichomegaly. *Ophthalm Plast Reconstr Surg* 2007; 23: 65–66 EBM K6
- [44] Lankerani L, Baron ED. Photosensitivity to exogenous agents. *J Cutan Med Surg* 2004; 8: 424–431
- [45] Lau SC, Shibata SI. Blepharoptosis following oxilaplatin administration. *J Oncol Pharm Pract* 2009; 15: 255–257 EBM K6
- [46] La Verde N, Garassino MC, Spinelli G et al. Reversible palpebral ptosis following oxaliplatin infusion. *Dig Liver Dis* 2007; 39: 1041 EBM K6
- [47] Lee AY, Jung SY. Two patients with isoniazid-induced photosensitive lichenoid eruptions confirmed by photopatch test. *Photodermatol Photoimmunol Photomed* 1998; 14: 77–78 EBM K6
- [48] Leibovitch I, Tamblin D, Casson R et al. Allergic reaction to hyaluronidase: a rare cause of orbital inflammation after cataract surgery. *Graefes Arch Clin Exp Ophthalmol* 2006; 244: 944–949 EBM K6
- [49] Lin SL, Liang SS. Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution. *J Ocul Pharmacol Ther* 1995; 11: 267–278 EBM K4
- [50] Marquez G, Herrera-Acosta E, Vidal I et al. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva). *In J Dermatol* 2009; 48: 97–98 EBM K6
- [51] Mendoca CO, Yates VM. Permanent facial hypopigmentation following treatment with imoquimod cream. *Clin Exp Dermatol* 2006; 31: 721–722 EBM K6
- [52] Miller D, Peczon JD, Whitworth CG. Corticosteroids and functions in the anterior segment of the eye. *Am J Ophthalmol* 1965; 59: 31–34
- [53] Oono S, Uga S. Two cases of bilateral Horner's syndrome induced by long-term use of adrenergic neuron blocking agents. *Nippon Ganka Gakkai Zasshi* 1979; 83: 521–530 EBM K6
- [54] Parsa FD, Wolff DR, Parsa NN et al. Upper eyelid ptosis repair after cataract extraction and the importance of Hering's test. *Plast Reconstr Surg* 2001; 108: 1527–1536 EBM K5
- [55] Peplinski LS, Albani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. *Optom Vis Sci* 2004; 81: 574–577 EBM K6
- [56] Price KS, Thomson DM. Localized unilateral periorbital edema induced by aspirin. *Ann Allergy Asthma Immunol* 1997; 79: 420–422 EBM K6
- [57] Rafiq R. Isolated periorbital angio-oedma induced by aspirin: a case report and review of the literature. *Dent Update* 2007; 34: 302–304 EBM K6
- [58] Rathod DJ, Shuttleworth GN. Anterior uveitis, poliosis, and skin hypopigmentation associated with topical chloramphenicol allergy following ptosis surgery. *Ophthalm Plast Reconstr Surg* 2007; 23: 318–319 EBM K6
- [59] Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. *CNS Drugs* 2010; 24: 501–526
- [60] Riley FC, Moyer NJ. Experimental Horner's syndrome: a pupillographic evaluation of guanethidine-induced adrenergic blockade in humans. *Am J Ophthalmol* 1970; 69: 442–447
- [61] Roberts G, Capell HA. The frequency and distribution of minocycline induced hyperpigmentation in a rheumatoid arthritis population. *J Rheumatol* 2006; 33: 1254–1257 EBM K5
- [62] Rowe F, Noonan C. Complications of botulinum toxin and their adverse effects. *Strabismus* 2009; 17: 139–142 EBM K5
- [63] Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications. Recognition and management. *Drugs* 2007; 67: 75–93
- [64] Sasaki S, Hozumi Y, Kondo S. Influence of prostaglandin F₂α and its analogues on hair regrowth and follicular melanogenesis in a murine model. *Exp Dermatol* 2005; 14: 323–328
- [65] Scheinfeld N. The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face. *Dermatol Online* 2005; 11: 9
- [66] Sharpe ED, Reynolds AC, Skuta GL et al. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. *Curr Eye Res* 2007; 32: 1037–1043 EBM K5
-

-
- [67] Shum DT, Smout MS, Pace WE et al. Unusual skin pigmentation from long-term methacycline and minocycline therapy. *Arch Dermatol* 1986; 122: 17–18 EBM K6
- [68] Sriprakash K, Godbolt A. Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma. *Australas J Dermatol* 2009; 50: 211–213 EBM K6
- [69] Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. *Expert Opin Drug Saf* 2007; 6: 431–443
- [70] Tappeiner C, Perren B, Iliev ME et al. Orbitale Fettgewebsatrophie bei lokaler Bimatoprost-Therapie – Kann Bimatoprost einen Enophthalmus verursachen? *Klin Monbl Augenheilkd* 2008; 225: 443–445 EBM K6
- [71] Tedeschi DH, Fowler PJ, Fujita T et al. Mechanisms underlying reserpine-induced ptosis and blepharospasm: evidence that reserpine decreases central sympathetic outflow in rats. *Life Sci* 1967; 6: 515–523
- [72] Tosti A, Pazzaglia M, Voudouris S et al. Hypertrichosis of the eyelashes caused by bimatoprost. *J Am Acad Dermatol* 2004; 51 (5 Suppl): S 149–150 EBM K6
- [73] Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularisation due to age-related macular degeneration and other causes: update. *Retina* 2005; 25: 119–134
- [74] Waheed K, Laganowski H. Bilateral poliosis and granulomatous anterior uveitis associated with latanoprost use and apparent hypotrichosis on its withdrawal. *Eye* 2001; 15: 347–349 EBM K6
- [75] Wand M. Latanoprost and hyperpigmentation of eyelashes. *Arch Ophthalmol* 1997; 115: 1206–1207 EBM K6
- [76] Wilcox CS, Heiser JF, Crowder AM, et al. Comparison of the effects on pupil size and accommodation of three regimens of topical dapiprazole. *Br J Ophthalmol* 1995; 79: 544–548 EBM K3
- [77] Wizemann A. Nekrotisierende Blepharitis bei Captopril-induzierter Agranulozytose. *Klin Monbl Augenheilkd* 1983; 182: 82–85 EBM K6
- [78] Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. *J Ocul Pharmacol Ther* 2009; 25: 471–472 EBM K6
- [79] Yüksel N, Güler C, Caglar Y et al. Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers. *Int Ophthalmol* 1992; 16: 337–342 EBM K1
- [80] Zgazarova S, Jedlickova H, Vaskü V. Skin adverse effects of amiodarone. *Vnitr Lek* 2009; 55: 976–980 EBM K6

Kap. 3

- [1] Abou-Elhamd KE. Two cases of Stevens-Johnson syndrome following intake of klavox with review of literature. *Eur Arch Otorhinolaryngol* 2009; 266: 1327–1330 EBM K6
- [2] Ahmed AH, McLarty DG, Sharma SK et al. Stevens-Johnson syndrome during treatment with cimetidine. *Lancet* 1978; 2: 433 EBM K6
- [3] Allen QB, Lowder CY, Meisler DM. Conjunctival necrosis following the administration of subconjunctival corticosteroid. *Ophthalmic Surg Lasers* 1998; 29: 779–780 EBM K6
- [4] Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. *Surv Ophthalmol* 2008; 53 (Suppl. 1): S 93–S 105
- [5] Almog Y, Monselise M, Almog C et al. The effect of oral treatment with beta blockers on the tear secretion. *Metab Pediatr Syst Ophthalmol* 1982; 6: 343–345 EBM K4
- [6] Aranda A, Mayorga C, Ariza A et al. IgE-mediated hypersensitivity reactions to methylprednisolone. *Allergy* 2010; 65:1376–1380 EBM K4
- [7] Aubry P, Goasguen J, Labegorre J. A case of Stevens-Johnson syndrome developed after tetanus. *Med Trop (Mars)* 1970; 30: 708–713 EBM K6
- [8] Arat YO, Yen MT. Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids. *Ophthal Plast Reconstr Surg* 2007; 23: 22–24 EBM K4
- [9] Balasubramanian S, Shobhana S, Padmasani LN et al. Carbamazepine hypersensitivity syndrome. *Indian Pediatr* 1999; 36: 98–99 EBM K6
- [10] Baudouin C, Liang H, Hamard P et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-Helper 1 and T-Helper 2 pathways. *Ophthalmology* 2008; 115: 109–115 EBM K4
- [11] Belkahlia A, Hillaire-Buys D, Dereure O et al. Stevens-Johnson syndrome due to mirtazapin – first case. *Allergy* 2009; 64: 1554 EBM K6
- [12] Bell RW, Ritchey JP. Subconjunctival nodules after amphotericin B injection. *Arch Ophthalmol* 1973; 90: 402–404 EBM

K6

- [13] Belyea DA, Dan JA, Stamper RL et al. Late onset of sequential multifocal bleb leaks after glaucoma filtration surgery with 5-fluorouracil and mitomycin C. *Am J Ophthalmol* 1997; 124: 40–45 EBM K5
- [14] Bielory L. Ocular toxicity of systemic asthma and allergy treatments. *Curr Allergy Asthma Rep* 2006; 6: 299–305
- [15] Black RA, Bensinger RE. Bilateral subconjunctival hemorrhage after acetylsalicylic acid overdose. *Ann Ophthalmol* 1982; 14: 1024–1025 EBM K6
- [16] Blondeau P, Rousseau JA. Allergic reactions to brimonidine in patients treated for glaucoma. *Can J Ophthalmol* 2002; 37: 21–26 EBM K5
- [17] Bodack MI. A warfarin-induced subconjunctival hemorrhage. *Optometry* 2007; 78: 113–118 EBM K6
- [18] Bomb BS, Purohit SD, Bedi HK. Stevens-Johnson syndrome caused by isoniazid. *Tubercle* 1976; 57: 229–230 EBM K6
- [19] Botelho C, Rodrigues J, Castel Branco MG. Allergic contact blepharoconjunctivitis with phenylephrine eyedrops – the relevance of late readings of intradermal tests. *Allergol Immunopathol (Madr)* 2007; 35: 157–158 EBM K6
- [20] Brasnu E, Brignole-Baudouin F, Riancho L et al. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. *Curr Eye Res* 2008; 33: 303–312
- [21] Brothers DM, Hidayat AA. Conjunctival pigmentation associated with tetracycline medication. *Ophthalmology* 1981; 88: 1212–1215 EBM K6
- [22] Brookes AB, Matoba AY. Chlorpromazine-induced anterior segment changes. *Arch Ophthalmol* 1992; 110: 126 EBM K6
- [23] Butt Z, Kaufmann D, McNab A et al. Drug-induced ocular cicatricial pemphigoid: a series of clinic-pathological reports. *Eye* 1998; 12: 285–290 EBM K5
- [24] Castaneda CP, Brandenburg NA, Bwire R et al. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients. *J Clin Oncol* 2009; 27: 156–157 EBM K6
- [25] Chen J, Dinh T, Woodward DF et al. Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy. *Cardiovasc Drug Rev* 2005; 23: 231–246
- [26] Chopra A, Drage LA, Hanson EM et al. Stevens-Johnson syndrome after immunization with smallpox, anthrax, and tetanus vaccines. *Mayo Clin Proc* 2004; 79: 1193–1196 EBM K6
- [27] Christophidis N, Vajda FJ, Lucas I et al. Ocular side effects with 5-fluorouracil. *Aus N Z J Med* 1979; 9: 143–144 EBM K4
- [28] Chung WH, Hung SI, Chen YT. Genetic predisposition of life-threatening antiepileptic-induced skin reactions. *Expert Opin Drug Saf* 2010; 9: 15–21
- [29] Cunliffe NA, Barnes AJ, Dunbar EM. Stevens-Johnson syndrome following astemizole therapy. *Postgrad Med J* 1995; 71: 383 EBM K6
- [30] Curley RK, Verbov JL. Stevens-Johnson syndrome due to tetracyclines – a case report (doxycycline) and review of the literature. *Clin Exp Dermatol* 1987; 12: 124–125 EBM K6
- [31] Dayani PN, Siddiqi OK, Holekamp NM. Safety of intravitreal injections in patients receiving warfarin anticoagulation. *Am J Ophthalmol* 2007; 144: 451–453 EBM K5
- [32] De Saint Jean M, Brignole F, Bringuier AF et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. *Invest Ophthalmol Vis Sci* 1999; 40: 619–630
- [33] De Serres G, Toth E, Menard S et al. Oculo-respiratory syndrome after influenza vaccination: trends over four influenza seasons. *Vaccine* 2005; 23: 3726–3732 EBM K5
- [34] Diamond JP, Chandna A, Williams C et al. Tranexamic acid-associated ligneous conjunctivitis with gingival and periteneal lesions. *Br J Ophthalmol* 1991; 75: 753–754 EBM K6
- [35] Dominguez-Lenero V, Barrera-Ledesma M, Romero-Alonso M et al. Stevens-Johnson syndrome and toxic hepatitis due to esomeprazol. *Farm Hosp* 2009; 33: 118–119 EBM K9
- [36] Dysseleer A, Buyschaert M, Fonck C et al. Acute interstitial nephritis and fatal Stevens-Johnson syndrome after propylthiouracil therapy. *Thyroid* 2000; 10: 713–716 EBM K6
- [37] Ebenezer D, Thorne JE. Recent advances in mucous membrane pemphigoid. *Curr Opin Ophthalmol* 2008; 19: 292–297
- [38] Eiseman AS, Flanagan JC, Brooks AB et al. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. *Ophthal Plast Reconstr Surg* 2003; 19: 216–224 EBM K4
- [39] Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry

-
- eye. *Graefes Arch Clin Exp Ophthalmol* 2008; 246: 1593–1601 EBM K4
- [40] Fiore PM, Jacobs IH, Goldberg DB. Drug-induced pemphigoid. A Spectrum of diseases. *Arch Ophthalmol* 1987; 105: 1660–1663 EBM K6
- [41] Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. *Surv Ophthalmol* 1992; 36: 259–285
- [42] Florez A, Roson E, Conde A et al. Toxic epidermal necrolysis secondary to timolol, dorzolamide, and latanoprost eyedrops. *J Am Acad Dermatol* 2005; 53: 909–911 EBM K6
- [43] Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. *Drug Saf* 2002; 25: 965–972 EBM K5
- [44] Fraunfelder FW, Fraunfelder FT, Ilingworth DR. Adverse ocular effects associated with niacin therapy. *Br J Ophthalmol* 1995; 79: 54–56 EBM K5
- [45] Fraunfelder FT. Orange tears. *Am J Ophthalmol* 1980; 89: 752 EBM K6
- [46] Fraunfelder FT. Drug-induced ocular side effects. Baltimore: Williams & Wilkins; 1996
- [47] Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/Toxic epidermal necrolysis. *Am J Clin Dermatol* 2000; 1: 349–360
- [48] Frucht-Pery J, Sugar J, Baum J et al. Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience. *Ophthalmology* 1997; 104: 2085–2093 EBM K5
- [49] Fuentes V, de Frutos C, de Barrio M et al. Unilateral conjunctival chemosis as a unique symptom of nonsteroidal anti-inflammatory drug intolerance. *J Investig Allergol Clin Immunol* 2007; 17: 62–64 EBM K6
- [50] Garty BZ. Stevens-Johnson syndrome associated with nystatin treatment. *Arch Dermatol* 1991; 127: 741–742 EBM K6
- [51] Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. *Drug Saf* 2002; 25: 233–250
- [52] Genvert GI, Cohen EJ, Donnenfeld ED et al. Erythema multiforme after use of topical sulfacetamide. *Am J Ophthalmol* 1985; 99: 465–468 EBM K6
- [53] Gianni L, Panzini I, Li S et al. International Breast Cancer Study Group (IBCSG). Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. *Cancer* 2006; 106: 505–513 EBM K5
- [54] Girling DJ. Letter: Ocular toxicity due to rifampicin. *Br Med J* 1976; 1: 585 EBM K6
- [55] Gottschalk HR, Stone OJ. Stevens-Johnson syndrome from ophthalmic sulfonamide. *Arch Dermatol* 1976; 112: 513–514 EBM K6
- [56] Grant WM, ed. Toxicology of the eye. Springfield, IL: Charles C. Thomas; 1974: 1085–1086
- [57] Guill MA, Goette DK, Knight CG et al. Erythema multiforme and urticaria. Eruptions induced by chemically related ophthalmic anticholinergic agents. *Arch Dermatol* 1979; 115: 742–743 EBM K6
- [58] Güngör IU, Beden U, Erkan D. Conjunctival necrosis due to subconjunctival injection of betamethasone in treatment of graft rejection after penetrating keratoplasty. *Ophthalmic Surg Lasers Imaging* 2005; 36: 348–349 EBM K6
- [59] Gupta HL, Dhemann R. Ampicillin induced Stevens-Johnson syndrome. *J Indian Med Assoc* 1979; 72: 188–189 EBM K6
- [60] Hällgren J, Tengvall-Linder M, Persson M et al. Stevens-Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug. *J Am Acad Dermatol* 2003; 49: (5 Suppl): 267–269 EBM K6
- [61] Halevy S, Ghislain PD, Mockenhaupt M et al. EuroSCAR Study Group. *J Am Acad Dermatol* 2008; 58: 25–32 EBM K4
- [62] Hazin R, Abuzetun JY, Daoud YJ et al. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients. *Curr Opin Ophthalmol* 2009; 20: 308–317
- [63] Hedges TR 3rd, Kenyon KR, Hanninen LA et al. Corneal and conjunctival effects of monobenzone in patients with vitiligo. *Arch Ophthalmol* 1983; 101: 64–68 EBM K6
- [64] Herbst RA, Uter W, Pirker C et al. Allergic and non-allergic periorbital dermatitis: patch test results of the Information Network of the departments of dermatology during a 5-year period. *Contact Dermatitis* 2004; 51: 13–19
- [65] Hiraki A, Aoe K, Murakami T et al. Stevens-Johnson syndrome induced by paclitaxel in a patient with squamous cell carcinoma of the lung: a case report. *Anticancer Res* 2004; 24: 1135–1137 EBM K6
- [66] Höh H. Lokalanästhetische Wirkung und subjektive Verträglichkeit von Carteolol 2% und Metipranolol 0,6% bei

-
- Augengesunden. *Klin Monbl Augenheilkd* 1989; 194: 241–248 EBM K1
- [67] Hoffer KJ. Pemphigoid related to epinephrine treatment. *Am J Ophthalmol* 1977; 83: 601 EBM K6
- [68] Hong J, Bielory L. Allergy to ophthalmic preservatives. *Curr Opin Allergy Clin Immunol* 2009; 9: 447–453
- [69] Honrubia F, Garcia-Sanchez J, Polo V et al. Conjunctival hyperemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a metaanalysis of randomized clinical trials. *Br J Ophthalmol* 2009; 93: 316–321
- [70] Horn W, Hoerauf H. Intravitreale Injektionen während antikoagulativer Therapie. *Klin Monbl Augenheilkd* 2008; 225: 217–219 EBM K4
- [71] Hornstein OP, Ruprecht KW. Fansidar-induced Stevens-Johnson syndrome. *N Engl J Med* 1982; 307: 1529–1530 EBM K6
- [72] Huang LY, Liao WC, Chiou CC et al. Fatal toxic epidermal necrolysis induced by carbamazepine treatment in a patient who previously had carbamazepine-induced Stevens-Johnson syndrome. *J Formos Med Assoc* 2007; 106: 1032–1037 EBM K6
- [73] Ikäheimo K, Kettunen R, Mäntyjärvi M. Visual functions and adverse ocular effects in patients with amiodarone medication. *Acta Ophthalmol Scand* 2002; 80: 59–63 EBM K5
- [74] Jameson CH, Solanki DL. Stevens-Johnson syndrome associated with etoposide therapy. *Cancer Treat Rep* 1983; 67: 1050–1051 EBM K6
- [75] Jao T, Tsai TH, Jeng JS. Aggrenox (Asasantin retard)-induced Stevens-Johnson syndrome. *Br J Clin Pharmacol* 2009; 67: 264–265 EBM K6
- [76] Jeanen N, Baudouin C, Pouliquen P et al. Ocular symptoms and signs with preserved and preserved-free glaucoma medications. *Eur J Ophthalmol* 2007; 17: 341–349 EBM K4
- [77] Jerstad KM, Warshaw E. Allergic contact dermatitis to latanoprost. *Am J Contact Dermat* 2002; 13: 39–41 EBM K6
- [78] Joost TV, Crone RA, Overdijk AD. Ocular cicatricial pemphigoid associated with practolol therapy. *Br J Dermatol* 1976; 94: 447–450 EBM K6
- [79] Karaoui LR, Cahine-Chakhtoura C. Fatal toxic epidermal necrolysis associated with minoxidil. *Pharmacotherapy* 2009; 29: 460–467 EBM K6
- [80] Kheirkhah SE, Liang L, Sheha H et al. Amniotic membrane transplantation as a new therapy for acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis. *Surv Ophthalmol* 2009; 54: 686–696
- [81] Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. *Br J Ophthalmol* 2006; 90: 819–822 EBM K5
- [82] Kiely PO, Johnson DM. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. *Rheumatology (Oxford)* 2002; 41: 631–637 EBM K4
- [83] Knowles S, Shear NH. Clinical risk management of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. *Dermatol Ther* 2009; 22: 441–451
- [84] Kuppens EV, de Jong CA, Stolwijk TR et al. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. *Br J Ophthalmol* 1995; 79: 339–342 EBM K4
- [85] La Grenade L, Lee L, Weaver J et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. *Drug Saf* 2005; 28: 917–924 EBM K5
- [86] Lass JH, Thoft RA, Dohlman CH. Idoxuridine-induced conjunctival cicatrization. *Arch Ophthalmol* 1983; 101: 747–750 EBM K6
- [87] Laurencin CT, Horan RF, Senatus PB et al. Stevens-Johnson-type reaction with vancomycin treatment. *Ann Pharmacother* 1992; 256: 1520–1521 EBM K6
- [88] Lazarov A, Amichai B. Skin reactions due to eye drops: report of two cases. *Cutis* 1996; 58: 363–364 EBM K6
- [89] Leckie MJ, Rees RG. Stevens-Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis. *Rheumatology* 2002; 41: 473–474 EBM K6
- [90] Leiker LL, Mehta BH, Pruchnicki MC et al. Risk factors and complications of subconjunctival hemorrhages in patients taking warfarin. *Optometry* 2009; 80: 227–231 EBM K5
- [91] Levi N, Bastuji-Garin S, Mockenhaupt M et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. *Pediatrics* 2009; 123: 297–304 EBM K4
- [92] Liang H, Baudouin C, Pauly A et al. Conjunctival and corneal reactions in rabbits following short- and repeated exposure

-
- to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. *Br J Ophthalmol* 2008; 92: 1275–1282
- [93] Lin AY, Baker BA. Verapamil-associated Stevens-Johnson syndrome. *DICP* 1989; 23: 987–988 EBM K6
- [94] Lin LC, Lai PC, Yang SF et al. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report. *Kaohsiung J Med Sci* 2009; 25: 82–86 EBM K6
- [95] Loche F, Schwarze HP, Thedenat B et al. Erythema multiforme associated with hepatitis B immunization. *Clin Exp Dermatol* 2000; 25: 167–168 EBM K6
- [96] Lonjou C, Borot N, Sekula P et al. RegiSCAR study group. *Pharmacogenomics* 2008; 18: 99–107 EBM K5
- [97] Loon SC, Liew G, Fung A et al. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. *Clin Experiment Ophthalmol* 2008; 36: 281–289
- [98] Lutz EG. Allergic conjunctivitis due to diazepam. *Am J Psychiatry* 1975; 132: 548 EBM K6
- [99] Maca SM, Amon M, Findl O et al. Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eye drops after cataract surgery. *Am J Ophthalmol* 2010; 149: 777–784 EBM K2
- [100] Macarol M, Fraunfelder FT. Pamidronate disodium and possible ocular adverse reactions. *Am J Ophthalmol* 1994; 118: 220–224 EBM K6
- [101] Mamishi S, Fattahi F, Pourpak Z et al. Severe cutaneous reactions caused by barbiturates in seven Iranian children. *Int J Dermatol* 2009; 48: 1254–1261 EBM K6
- [102] Mancuso G, Berdondini RM. Allergic contact blepharoconjunctivitis from dorzolamide. *Contact Dermatitis* 2001; 45: 243 EBM K6
- [103] Manni G, Centofanti M, Sacchetti M et al. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. *J Glaucoma* 2004; 13: 163–167 EBM K5
- [104] Marti-Huguet T, Quintana M, Cabiro I. Cicatricial pemphigoid associated with D-penicillamine treatment. *Arch Ophthalmol* 1989; 107: 1115 EBM K6
- [105] Mathers WD, Shields WJ, Sachdev MS et al. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. *Cornea* 1991; 10: 286–290
- [106] McAllum P, Slomovic A. Scleral and conjunctival pigmentation following minocycline therapy. *Can J Ophthalmol* 2007; 42: 626–627 EBM K6
- [107] McArthur JE, Dymont PG. Stevens-Johnson syndrome with hepatitis following therapy with ampicillin and cephalixin. *N Z Med J* 1975; 81: 390–392 EBM K6
- [108] Messmer E, Font RL, Sheldon G et al. Pigmented conjunctival cysts following tetracycline/minocycline therapy. Histochemical and electron microscopic observations. *Ophthalmology* 1983; 90: 1462–1468 EBM K6
- [109] Mitra A, McElvanney A. Prophylactic subconjunctival cefuroxime during cataract surgery in patients with a penicillin allergy. *Ann Ophthalmol (Skokie)* 2006; 38: 293–295
- [110] Morrison VL, Kikkawa DO, Herndier BG et al. Tetracycline induced green conjunctival pigment deposits. *Br J Ophthalmol* 2005; 89: 1372–1373 EBM K6
- [111] Moss SE, Klein R, Klein BE. Long-term incidence of dry eye in an older population. *Optom Vis Sci* 2008; 85: 668–674 EBM K4
- [112] Mukul, Verma G. Propranolol induced Steven-Johnson syndrome. *J Assoc Physicians India* 1989; 37: 797–798 EBM K6
- [113] Mullins RJ, Lones R, Dutta B. Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops. *Australas J Dermatol* 2004; 45: 151–152 EBM K6
- [114] Munshi V, Ahluwalia H. Erythema mutliforme after use of topical dorzolamide. *J Ocul Pharmacol Ther* 2008; 24: 91–93 EBM K6
- [115] Naito T, Shiota H, Mimura Y. Side effects in the treatment of herpetic keratitis. *Curr Eye Res* 1987; 6: 237–239 EBM K5
- [116] Northington ME, Huang CC. Dry eyes and superficial punctuate keratitis: a complication of treatment of glabellar dynamic rhytides with botulinum exotoxin A. *Dermatol Surg* 2004; 30: 1515–1517 EBM K6
- [117] Ofoma UR, Chapnick EK. Fluconazole induced toxic epidermal necrolysis: a case report. *Cases J* 2009; 2: 9071 EBM K6
- [118] Ogasawara K, Tomitsuka N, Kobayashi M et al A. Stevens-Johnson syndrome associated with intravenous acetazolamide administration for evaluation of cerebrovascular reactivity. Case report. *Neurol Med Chir (Tokyo)* 2006; 46: 161–163 EBM K6

-
- [119] Ohashi Y, Ebihara N, Fujishima A et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. *J Ocul Pharmacol Ther* 2010; 26: 165–174 EBM K1
- [120] Oliver TK, Havener WH. Eye manifestations of chronic Vitamin A intoxication. *Arch Ophthalmol* 1958; 60: 19–22 EBM K6
- [121] Osborne SA, Montgomery DM, Morris D et al. Alphagan allergy may increase the propensity for multiple eye-drop allergy. *Eye* 2005; 19: 129–137 EBM K5
- [122] Ousler GW 3rd, Workman DA, Torkildsen GL. An open-label, investor-masked, crossover study of the ocular drying effect of two antihistamines, topical epinastin and systemic loratidin, in adult volunteers with seasonal allergic conjunctivitis. *Clin Ther* 2007; 29: 611–616 EBM K2
- [123] Pahk R, Azu MC, Taira BR et al. Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodeficiency virus. *Clin Exp Dermatol* 2009; 34: e775–777 EBM K6
- [124] Panda A, Das GK, Khokhar S et al. Efficacy of four antiviral agents in the treatment of uncomplicated herpetic keratitis. *Can J Ophthalmol* 1995; 30: 256–258 EBM K1
- [125] Pantano F, Silletta M, Iovieno A et al. Stevens-Johnson syndrome associated with reduced tear production complicating the use of cetuximab and panitumumab. In *J Colorectal Dis* 2009; 24: 1247–1248 EBM K6
- [126] Peyri J, Servitje O, Ribera M et al. Cicatricial pemphigoid in a patient with rheumatoid arthritis treated with D-penicillamine. *J Am Acad Dermatol* 1986; 14: 681 EBM K6
- [127] Pichichero ME. Cephalosporins can be prescribed safely for penicillin-allergic patients. *J Fam Pract* 2006; 55: 106–112
- [128] Pitche P, Mouzou T, Padonou C et al. Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicine-isoniazid: report of 8 cases in HIV-infected patients in Togo. *Med Trop (Mars)* 2005; 65: 359–362 EBM K6
- [129] Pisella PJ, Lala E, Parier V et al. Retentissement conjonctival des conservateurs: étude comparative de collyres bêta-bloquants conservés et non conservés chez des patients glaucomateux. *J Fr Ophtalmol* 2003; 26: 675–679 EBM K4
- [130] Porcel SL, Cumplido JA, de la Hoz B et al. Anaphylaxis to calcitonin. *Allergol Immunopathol (Madr)* 2000; 28: 243–245 EBM K6
- [131] Prabhasawat P, Tarinvorakup P, Tesavibul N et al. Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. *Cornea* 2005; 24: 443–448 EBM K5
- [132] Radaelli F, Vener C, Ripamonti F et al. Conjunctival hemorrhagic events associated with imatinib mesylate. *Int J Hematol* 2007; 86: 390–393 EBM K5
- [133] Remick RA. Anticholinergic side effects of tricyclic antidepressants and their management. *Prog Neuropsychopharmacol Biol Psychiatry* 1988; 12: 225–231
- [134] Resano A, Esteve C, Fernandez Benitez M. Allergic contact blepharoconjunctivitis due to phenylephrine eye drops. *J Investig Allergol Clin Immunol* 1999; 9: 55–57 EBM K6
- [135] Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. *CNS Drug* 2010; 24: 501–526
- [136] Rotunda A, Hirsch RJ, Scheinfeld N et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medication. *Acta Derm Venereol* 2003; 83: 1–9 EBM K5
- [137] Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. *World J Gastroenterol* 2009; 15: 4449–4452 EBM K6
- [138] Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications. Recognition and management. *Drugs* 2007; 67: 75–93
- [139] Sarkar SK, Purohit SD, Sharma TN et al. Stevens-Johnson syndrome caused by streptomycin. *Tubercle* 1982; 63: 137–138 EBM K6
- [140] Sarma N. Stevens-Johnson syndrome and toxic epidermal necrolysis overlap due to oral temozolamide and cranial radiotherapy. *Am J Clin Dermatol* 2009; 10: 264–267 EBM K6
- [141] Sawada Y, Sugita K, Kabashima R et al. Docetaxel-induced Stevens-Johnson syndrome with regenerating epidermis composed of atypical keratinocytes. *J Eur Acad Dermatol Venereol* 2009; 23: 1333–1335 EBM K6
- [142] Schaumberg DA, Dana R, Buring JE et al. Prevalence of dry eye disease among US men: estimates from the physicians'health studies. *Arch Ophthalmol* 2009; 127: 763–768
- [143] Schlote T, Freudenthaler N, Gelissen F. Akutes Winkelblockglaukom nach massiver intraokularer Blutung bei exsudativer altersbedingter Makuladegeneration unter gerinnungshemmender Therapie. *Ophthalmologie* 2005; 102: 1090–1096 EBM K6
-

-
- [144] Schuster V, Seregard S. Ligneous conjunctivitis. *Surv Ophthalmol* 2003; 48: 369–388
- [145] Shirato S, Kagaya F, Suzuki Y et al. Stevens-Johnson syndrome induced by methazolamide treatment. *Arch Ophthalmol* 1997; 115: 550–553 EBM K6
- [146] Shuttleworth D, Graham-Brown RA, Hutchinson PE et al. Cicatricial pemphigoid in D-penicillamine treated patients with rheumatoid arthritis – a report of three cases. *Clin Exp Dermatol* 1985; 10: 392–397 EBM K6
- [147] Sing J O'Brien C, Chawla HB. Success rate and complications of intraoperative 0.2 mg/ml mitomycin C in trabeculectomy surgery. *Eye* 1995; 9: 460–466 EBM K4
- [148] Singer L, Knobel B, Romem M. Influence of systemic administrated beta-blockers on tear secretion. *Ann Ophthalmol* 1984; 16: 728–729 EBM K4
- [149] Skarpaas IJ. An unexpected reaction towards disodium cromoglycate. *Allergy* 1987; 42: 318–319 EBM K6
- [150] Skowronski DM, Strauss B, De Serres G et al. Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event? *Clin Infect Dis* 2003; 36: 705–713 EBM K5
- [151] Smith EV, Pynn MC, Blackford S et al. Stevens-Johnson syndrome secondary to oseltamivir (Tamiflu). *Br J Gen Pract* 2010; 60: 133–134 EBM K6
- [152] Soparker CN, Wilhelmus KR, Koch DD et al. Acute and chronic conjunctivitis due to over-the-counter ophthalmic decongestants. *Arch Ophthalmol* 1997; 115: 34–38 EBM K5
- [153] Spinler SA, Globus NJ, Raymond JZ et al. Indapamide-associated Stevens-Johnson syndrome. *Cutis* 1992; 50: 200–202 EBM K6
- [154] Srinivasan S, Prasad S. Conjunctival necrosis following intravitreal injection of triamcinolone acetonide. *Cornea* 2005; 24: 1027–1028 EBM K6
- [155] Sternlieb P, Robinson RM. Stevens-Johnson syndrome plus toxic hepatitis due to ibuprofen. *N Y State J Med* 1978; 78: 1239–1243 EBM K6
- [156] Studdiford J, Oppenheim L, McCann E et al. Erythema multiforme after meningitis vaccine: patient safety concerns with regard immunization. *Pharmacotherapy* 2006; 26: 1658–1661 EBM K6
- [157] Sud RN, Grewal SS. Stevens Johnson syndrome due to Diamox. *Indian J Ophthalmol* 1981; 29: 101–103 EBM K6
- [158] Surjapranata FJ, Rahaju NN. A case of Stevens-Johnson's syndrome caused by ethambutol. *Paediatr Indones* 1979; 19: 195–201 EBM K6
- [159] Taaffe A, O'Brien C. A case of Stevens-Johnson syndrome associated with the anti-convulsants sulthiame and ethosuximide. *Br Dent J* 1975; 138: 172–174 EBM K6
- [160] Tappeiner C, Sarra GM, Abegg M. Abuse of vasoconstrictive eyedrops mimicking an ocular pemphigoid. *Eur J Ophthalmol* 2009; 19: 129–132 EBM K6
- [161] Tassaneeyakul W, Jantararungtong T, Chen P et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. *Pharmacogenet Genomics* 2009; 19: 704–709 EBM K4
- [162] Taylor JW, Cleary JD, Atkinson RC. Stevens-Johnson syndrome associated with diltiazem. *Clin Pharm* 1990; 9: 948–950 EBM K6
- [163] Tebruegge M, Pantazidou A. Images in HIV/AIDS. Stevens-Johnson syndrome associated with thalidomide treatment in HIV infection. *AIDS Read* 2008; 18: 519–520 EBM K6
- [164] Tebruegge M, Ritz N, Connell T et al. Human immunodeficiency virus-infected boy with Stevens-Johnson syndrome caused by nevirapine. *Pediatr Infect Dis J* 2008; 27: 1041–1042 EBM K6
- [165] Thorne J, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. *Ophthalmology* 2004; 111: 45–52 EBM K5
- [166] Torres MJ, Canto G. Hypersensitivity reactions to corticosteroids. *Curr Opin Allergy Clin Immunol* 2010; 10: 273–279
- [167] Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. *Epilepsia* 1998; 39 (Suppl. 7): 822–826 EBM K5
- [168] Su CY, Yang YC, Peng CF et al. Risk of microbial contamination of unit-dose eyedrops within twenty four hours after first opening. *J Formos Med Assoc* 2005; 104: 968–971
- [169] Umez-Eronini EM. Conjunctivitis due to ketoprofen. *Lancet* 1978; 2: 737 EBM K6
- [170] Uter W, Menezes de Padua C, Pfahlberg A et al. Kontaktallergien gegen ophthalmologische Lokalthapeutika – eine epidemiologische Risikobewertung. *Klin Monbl Augenheilkd* 2009; 226: 48–53
-

-
- [171] Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. *Acta Ophthalmol Suppl (Oxf)* 2008; 242: 7–13 EBM K2
- [172] Valdivieso R, Subiza J, Varela-Losada S et al. Severe allergic conjunctivitis and chemosis caused by disodium cromoglycate. *J Invest Allergol Clin Immunol* 1998; 8: 58–60 EBM K6
- [173] Van der Linde AA, Pillen S, Gerrits GP et al. Stevens-Johnson syndrome in a child with chronic mercury exposure and 2,3-dimercaptopropane-1-sulfonate (DMPS) therapy. *Clin Toxicol (Phila.)* 2008; 46: 479–481 EBM K6
- [174] Walinga H, van Beugen L. Stevens-Johnson syndrome following administration of griseofulvin. *Ne Tijdschr Geneesk* 1981; 125: 759–760 EBM K6
- [175] Wanat KA, Anadkat MJ, Klebotka PA. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole. *J Am Acad Dermatol* 2009; 60: 589–594 EBM K5
- [176] Ward B, McCulley JP, Segal RJ. Dermatologic reaction in Stevens-Johnson syndrome after ophthalmic anesthesia with proparacaine hydrochloride. *Am J Ophthalmol* 1978; 86: 133–135 EBM K6
- [177] Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. *Mayo Clin Proc* 2010; 85: 131–138 EBM K5
- [178] Williams DA. Stevens-Johnson syndrome after erythromycin therapy while deployed at sea. *Mil Med* 2000; 165: 636–637 EBM K6
- [179] Williams GC, Orengo-Nania S, Gross RL. Incidence of brimonidine allergy in patients previously allergic to apraclonidine. *J Glaucoma* 2000; 9: 235–238 EBM K5
- [180] Wilson FM 2nd. Adverse external ocular effects of topical ophthalmic therapy: an epidemiologic, laboratory, and clinical study. *Trans Am Ophthalmol Soc* 1983; 81: 854–965 EBM K5
- [181] Wong SS. Stevens-Johnson syndrome induced by clofibrate. *Acta Derm Venereol* 1994; 74: 475 EBM K6
- [182] Wright P. Untoward effects associated with practolol administration: oculomucocutaneous syndrome. *Br Med J* 1975; 1: 595–598 EBM K6
- [183] Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. *Curr Opin Ophthalmol* 2007; 18: 134–139
- [184] Zamir E, Pe'er. Necrotizing conjunctival ulceration following subconjunctival depot methylprednisolone injection. *Ophthalmic Surg Lasers* 1999; 30: 565–566 EBM K6
- [185] Zollo E, Cusano F, Argenone A et al. A case of Stevens-Johnson syndrome possibly induced by amifostine during radiotherapy. *Tumor* 2007; 93: 634–635 EBM K6

Kap. 4

- [1] Ahmadi MA, Esmaeli B. Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly. *Arch Ophthalmol* 2001; 119: 1802–1804 EBM K5
- [2] Bradbury JA, Rennie IG, Psons MA. Adrenaline dacryolith: detection by ultrasound examination of the nasolacrimal duct. *Br J Ophthalmol* 1988; 72: 935–937 EBM K6
- [3] Christophidis N, Vajda FJ, Lucas I et al. Ocular side effects with 5-fluorouracil. *Aust N Z J Med* 1979; 9: 143–144 EBM K4
- [4] Eiseman AS, Flanagan JC, Brooks AB et al. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. *Ophthal Plast Reconstr Surg* 2003; 19: 216–224 EBM K5
- [5] Esmaeli B, Amin S, Valero V et al. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. *J Clin Oncol* 2006; 24: 3619–3622 EBM K4
- [6] Fezza JP, Wesley RE, Klippenstein KA. The treatment of punctual and canalicular stenosis in patients on systemic 5-FU. *Ophthalmic Surg Lasers* 1999; 30: 105–108 EBM K5
- [7] Fraunfelder FT. Drug-induced ocular side effects. 4th ed. Baltimore: Williams & Wilkins 1996: 10, 248, 445
- [8] Fraunfelder FW, Solomon J, Druker BJ et al. Ocular side-effects associated with imatinib mesylate (Gleevec). *J Ocul Pharmacol Ther* 2003; 19: 371–375 EBM K5
- [9] Hassan A, Hurwitz JJ, Burkes RL. Epiphora in patients receiving systemic 5-fluorouracil therapy. *Can J Ophthalmol* 1998; 33: 14–19 EBM K4
- [10] Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. *Br J Ophthalmol* 2006; 90: 819–822 EBM K5

-
- [11] McCartney E, Valluri S, Rushing D et al. Upper and lower system nasolacrimal duct stenosis secondary to paclitaxel. *Ophthal Plast Reconstr Surg* 2007; 23: 170–171 EBM K6
 - [12] Narioka J, Ohashi Y. Changes in lumen width of nasolacrimal drainage system after adrenergic and cholinergic stimulation. *Am J Ophthalmol* 2006; 141: 689–698 EBM K4
 - [13] Spaeth GL. Nasolacrimal duct obstruction caused by topical epinephrine. *Arch Ophthalmol* 1967; 77: 355–357 EBM K6
 - [14] Wood JR, Anderson RL, Edwards JJ. Phospholine iodide toxicity and Jones' tubes. *Ophthalmology* 1980; 87: 346–349 EBM K6
 - [15] Zimmermann TJ, Wheeler TM. Miotics: side effects and ways to avoid them. *Ophthalmology* 1982; 89: 76–80

Kap. 5

- [1] Bindlish R, Condon GP, Schlosser JD et al. Efficacy and safety of mitomycin-C in primary trabeculectomy: five year follow-up. *Ophthalmology* 2002; 109: 1336–1341 EBM K5
- [2] Brodgen RN, Fitton A. Rifabutin: a review of its antimicrobial activity, pharmacokinetic properties, and therapeutic efficacy. *Drugs* 1994; 47: 983–1009
- [3] Fourman S. Scleritis after glaucoma filtering surgery with mitomycin C. *Ophthalmology* 1995; 102: 1569–1571 EBM K6
- [4] Fraunfelder FW, Fraunfelder FT, Bree J. Scleritis and other ocular side effects associated with pamidronate disodium. *Am J Ophthalmol* 2003; 135: 219–222 EBM K6
- [5] Fraunfelder FT. Drug-induced ocular side effects. Baltimore: Williams & Wilkins; 1996: 284–293, 325–326
- [6] Fraunfelder FT, Randall JA. Minocycline-induced scleral pigmentation. *Ophthalmology* 1997; 104: 936–938 EBM K6
- [7] French DD, Margo CE. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. *Retina* 2008; 28: 889–893 EBM K5
- [8] Gartner S, Rubner K. Calcified scleral nodules in hypervitaminosis D. *Am J Ophthalmol* 1955; 39: 658 EBM K6
- [9] Henderson RP, Lander R. Scleral discoloration associated with long-term prednisone administration. *Cutis* 1984; 34: 76 EBM K6
- [10] Karalezli A, Kucukerdonmez C, Borazan M et al. Successful treatment of necrotizing scleritis after conjunctival autografting for pterygium with amniotic membrane transplantation. *Orbit* 2010; 29: 88–90 EBM K6
- [11] Le Garrec J, Marcelli C, Mouriaux F. Les anti-Tnf peuvent-ils induire des scléro-uvéïtes? *J Fr Ophtalmol* 2009; 32: 511.e1–6 EBM K6
- [12] Macarol M, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. *Am J Ophthalmol* 1994; 118: 220–224 EBM K6
- [13] Maquet JA, Dios E, Aragon J et al. Protocol for mitomycin C in glaucoma surgery. *Acta Ophthalmol Scand* 2005; 83: 196–200 EBM K5
- [14] Mbekeani JN, Slamovits TL, Schwartz BH et al. Ocular inflammation associated with alendronate therapy. *Arch Ophthalmol* 1999; 11: 837–838 EBM K6
- [15] Morrow GL, Abbott RL. Minocycline-induced scleral, dental, and dermal pigmentation. *Am J Ophthalmol* 1998; 125: 396–397 EBM K6
- [16] Panda A, Das GK, Tuli SW et al. Randomized trial of intraoperative mitomycin C in surgery for pterygium. *Am J Ophthalmol* 1998; 125: 59–63 EBM K3
- [17] Rachmiel R, Leiba H, Levartovsky S. Results of treatment with topical mitomycin C 0,02% following excision of primary pterygium. *Br J Ophthalmol* 1995; 79: 233–236 EBM K5
- [18] Salati C, Migliorati G, Brusini P. Scleroretinal necrosis after a subconjunctival injection of gentamicin in a patient with a surgically repaired episcleral retinal detachment. *Eur J Ophthalmol* 2004; 14: 575–577 EBM K6
- [19] Santamaria J. Steroidal agents: their systemic and ocular complications. *Ocular Inflammation* 1983; 1: 19
- [20] Tsai YY, Lin JM, Shy JD. Acute scleral thinning after pterygium excision with intraoperative mitomycin C: a case report of scleral dellen after bare sclera technique and review of the literature. *Cornea* 2002; 21: 227–229 EBM K6
- [21] Turgeon PW, Slamovits TL. Scleritis as the presenting manifestation of procainamide-induced lupus. *Ophthalmology* 1989; 96: 68–71 EBM K6
- [22] Wan Norliza WM, Raihan IS, Azwa JA et al. Scleral melting 16 years after pterygium excision with topical Mitomycin C adjuvant therapy. *Cont Lens Anterior Eye* 2006; 29: 165–167 EBM K6

Kap. 6

- [1] Albert DM, Wong VG. Ocular complications of vincristine therapy. *Arch Ophthalmol* 1967; 78: 709–713 EBM 6
- [2] Alster Y, Varssano D, Loewenstein et al. Delay of corneal wound healing in patients treated with colchizine. *Ophthalmology* 1997; 104: 118–119 EBM K6
- [3] Althaus C, Schelle C, Sundmacher R. Akute bandförmige Keratopathie nach intraokularer Fibrinolyse mit rekombinantem Tissue-Plasminogen-Aktivator (tr-PA). *Klin Monbl Augenheilkd* 1996; 209: 318–321 EBM K6
- [4] Aragona P, Di Pietro R. Is it safe to use topical NSAIDs for corneal sensitivity in Sjögren's syndrome patients? *Expert Opin Drug Saf* 2007; 6: 33–43
- [5] Aragona P, Stilo A, Ferreri F et al. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren's syndrome patients. *Eye* 2005; 19: 535–539 EBM K3
- [6] Biedner BZ, Rothkoff L, Friedman L et al. Colchizine suppression of corneal wound healing after strabismus surgery. *Br J Ophthalmol* 1977; 61: 496–497 EBM K6
- [7] Bonnet P. Sur une forme particuliere de granulations miliaires de l'iris. *Bull Soc Ophthalmol Paris* 1937; 49: 413–416 EBM K6
- [8] Brazier DJ, Hitchings RA. Atypical band keratopathy following long-term pilocarpine treatment. *Br J Ophthalmol* 1989; 73: 294–296 EBM K6
- [9] Bron AJ, McLendon BF, Camp AV. Epithelial deposits of gold in the cornea in patients receiving systemic therapy. *Am J Ophthalmol* 1979; 88: 354–360 EBM K6
- [10] Burns CA. Indomethacin, reduced retinal sensitivity, and corneal deposits. *Am J Ophthalmol* 1968; 66: 825–835 EBM K6
- [11] Castillo A, Benitez del Castillo JM, Toledano N et al. Deposits of topical norfloxacin in the treatment of bacterial keratitis. *Cornea* 1997; 16: 420–423 EBM K6
- [12] Cauchi P, Azuara-Blanco A, McKenzie J. Corneal toxicity and inflammation secondary to retained perfluorodecalin. *Am J Ophthalmol* 2005; 140: 322–323 EBM K6
- [13] Chamberlain WP, Boles DJ. Edema of cornea precipitated by quinacrine (Atabrine). *Arch Ophthalmol* 1946; 35: 120–134 EBM K6
- [14] Chang KC, Jeong JH, Kim MK et al. The effect of amantadine on corneal endothelium in subjects with Parkinson's disease. *Ophthalmology* 2010; 117: 1214–1219 EBM K4
- [15] Chowers I, Frucht-Pery J, Siganos ChS et al. Vinblastine toxicity to the ocular surface. *Anti-Cancer Drugs* 1996; 7: 805–808 EBM K6
- [16] Claerhout I, Kestelyn P, Meire F et al. Corneal deposits after the topical use of ofloxacin in two children with vernal keratoconjunctivitis. *Br J Ophthalmol* 2003; 87: 646 EBM K6
- [17] Cogan DG, Albright F, Bartter FC. Hypercalcemia and band keratopathy. *Arch Ophthalmol* 1948; 40: 624–638 EBM K6
- [18] Coutinho AB, Cheema D, Pereira PR et al. Corneal endothelial deposits associated with rifabutin use. *J Ocul Pharmacol Ther* 2005; 21: 166–169 EBM K5
- [19] Cullen AP, Chou BR. Keratopathy with low dose chloroquine therapy. *J Am Optom Assoc* 1986; 57: 368–372 EBM K5
- [20] Diamond JP, Chandna A, Williams C et al. Tranexamic acid-associated ligneous conjunctivitis with gingival and peritoneal lesions. *Br J Ophthalmol* 1991; 75: 753–754 EBM K6
- [21] Dosso A, Rungger-Brändle E. In vivo confocal microscopy in hydroxychloroquine-induced keratopathy. *Graefes Arch Clin Exp Ophthalmol* 2007; 245: 318–320 EBM K6
- [22] Drenckhanh D, Jacobi B, Lullmann-Rauch R. Corneal lipidosis in rats treated with amphiphilic cationic drugs. *Arzneimittelforschung* 1983; 33: 827–831
- [23] Durham RA, Sawyer DC, Keller WF et al. Topical ocular anaesthetics in ocular irritancy testing: a review. *Labaratory Animal Science* 1992; 42: 535–541
- [24] Eleftheriadis H, Cheong M, Sandeman S et al. Corneal toxicity secondary to inadvertent use of benzalkonium chloride preserved viscoelastic material in cataract surgery. *Br J Ophthalmol* 2002; 86: 299–305 EBM K5
- [25] Erdurmus M, Selcoki Y, Yagci R et al. Amiodarone-induced keratopathy: full-thickness corneal involvement. *Eye Contact Lens* 2008; 34: 131–132 EBM K6
- [26] Esquenazi S. Bilateral reversible corneal edema associated with amantadine use. *J Ocul Pharmacol Ther* 2009; 25: 567–570 EBM K6

-
- [27] Flach AJ. Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs. *Trans Am Ophthalmol Soc* 2001; 99: 205–210 EBM K5
- [28] Ferracuti S, Leardi MG, Cruccu G et al. Analgesic-antiinflammatory drugs inhibit orbicularis oculi reflexes in humans via a central mode of action. *Prog Neuropsychopharmacol Biol Psychiatry* 1994; 18: 101–113 EBM K2
- [29] Foerster CG, Cursiefen C, Kruse FE. Persisting corneal erosion under cetuximab (Erbix) treatment (epidermal growth factor receptor antibody). *Cornea* 2008; 27: 612–614 EBM K6
- [30] Font RL, Sobol W, Mtoba A. Polychromatic corneal and conjunctival crystals secondary to clofazimine therapy in a leper. *Ophthalmology* 1989; 96: 311–315 EBM K6
- [31] Fraunfelder FT, LaBraico JM, Meyer SM. Adverse ocular reactions possibly associated with isotretinoin. *Am J Ophthalmol* 1985; 100: 96–97 EBM K5
- [32] Fraunfelder FT, Meyer SM. Amantadine and corneal deposits. *Am J Ophthalmol* 1990; 110: 96–97 EBM K6
- [33] Fraunfelder FT. *Drug-induced side effects*. 4th ed. Baltimore: Williams & Wilkins; 1996: 87–88, 99–101
- [34] Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. *Am J Ophthalmol* 2001; 132: 299–305
- [35] Gabison EE, Chastang P, Menashi S et al. Late corneal perforation after photorefractive keratectomy associated with topical diclofenac: involvement of matrix metalloproteinases. *Ophthalmology* 2003; 110: 1626–1631 EBM K6
- [36] Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. *Drug Saf* 2002; 25: 233–250
- [37] Gibson JM, Fielder AR, Garner A et al. Severe ocular side effects of perhexiline maleate: case report. *Br J Ophthalmol* 1984; 68: 553–560 EBM K6
- [38] Goldenfeld M, Krupin T, Ruderman JM et al. 5-Fluorouracil in initial trabeculectomy. A prospective, randomized multicenter study. *Ophthalmology* 1994; 101: 1024–1029 EBM K2
- [39] Gookhale NS, Vemuganti GK. Diclofenac-induced acute corneal melt after collagen crosslinking for keratoconus. *Cornea* 2010; 29: 117–119 EBM K6
- [40] Grüb M, Leitritz M, Mielke J et al. Effekt von Timolol auf die zentrale Hornhautdicke und Endothelzelldicke. *Klin Monbl Augenheilkd* 2006; 223: 894–898 EBM K3
- [41] Hatanaka M, Vessani RM, Elias IR et al. The effect of prostaglandin analogs and prostamide on central corneal thickness. *J Ocul Pharmacol Ther* 2009; 25: 51–53 EBM K4
- [42] Haug SJ, Friedman AH. Identification of amiodarone in corneal deposits. *Am J Ophthalmol* 1991; 111: 518–519
- [43] Hedges TR 3rd, Kenyon KR, Hanninen LA et al. Corneal and conjunctival effects of monobenzone in patients with vitiligo. *Arch Ophthalmol* 1983; 101: 64–68 EBM K6
- [44] Hobbs HE, Eadie SP, Somerville F. Ocular lesions after treatment with chloroquine. *Br J Ophthalmol* 1961; 62: 216–220 EBM K5
- [45] Höh H. Lokalanästhetische Wirkung und subjektive Verträglichkeit von Carteolol 2% und Metipranolol 0,6% bei Augengesunden. *Klin Monbl Augenheilkd* 1989; 194: 241–248 EBM K1
- [46] Holland EJ, Stein CA, Palestine AG et al. Suramin keratopathy. *Am J Ophthalmol* 1988; 196: 216–220 EBM K6
- [47] Holland SP, Chang CW, Vagh M et al. Corneal endothelial deposits in patients with HIV infection or AIDS: epidemiologic evidence of the contribution of rifabutin. *Can J Ophthalmol* 1999; 34: 204–209 EBM K5
- [48] Hopen C, Mondino BJ, Johnson BL et al. Corneal toxicity with systemic cytarabine. *Am J Ophthalmol* 1981; 91: 500–504 EBM K4
- [49] Hou YC, Wang IJ, Hu FR. Ring keratitis associated with topical abuse of a dilute anesthetic after refractive surgery. *J Formos Med Assoc* 2009; 108: 967–972 EBM K6
- [50] Hughes EH, Pretorius M, Eleftheriadis H et al. Long-term recovery of the human corneal endothelium after toxic injury by benzalkonium chloride. *Br J Ophthalmol* 2007; 91: 1460–1463 EBM K5
- [51] Hull DS, Csukas S, Green K. Chlorpromazine-induced corneal endothelial phototoxicity. *Invest Ophthalmol Vis Sci* 1982; 22: 502–508
- [52] Johnson AW, Buffaloe WJ. Chlorpromazine epithelial keratopathy. *Arch Ophthalmol* 1966; 76: 664–667 EBM K6
- [53] Kachi S, Hirano K, Takesue et al. Unusual corneal deposits after the topical use of cyclosporine as eyedrops. *Am J Ophthalmol* 2000; 130: 667–669 EBM K6
-

-
- [54] Kaiser-Kupfer MI, Lippmann ME. Tamoxifen retinopathy. *Cancer Treat Rep* 1978; 62: 315–320 EBM K6
- [55] Katz GJ, Higginbotham EJ, Lichter PR et al. Mitomycin C versus 5-fluorouracil in high risk glaucoma filtering surgery. Extended follow-up. *Ophthalmology* 1995; 102: 1263–1269 EBM K3
- [56] Konowal A, Morrison JC, Brown SV et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. *Am J Ophthalmol* 1999; 127: 403–406 EBM K5
- [57] Kohlhaas M, Mammen A, Richard G. Veränderungen der Hornhautsensibilität nach topischer Dorzolamidgabe. Eine vergleichende Studie. *Ophthalmologie* 1997; 94: 424–427 EBM K4
- [58] Konen W, Severin M, Kilp H. Therapie des cornealen Amiodaronschadens bei Fortführung der vitalen, antiarrhythmischen Therapie. *Fortschr Ophthalmol* 1984; 81: 210–213 EBM K6
- [59] Lass JH, Khosrof SA, Laurence JK et al. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. *Arch Ophthalmol* 1998; 116: 1003–1010 EBM K1
- [60] Jeng BH, Galor A, Lee MS et al. Amantadine-associated corneal edema potentially irreversible even after cessation of the medication. *Ophthalmology* 2008; 115: 1540–1544 EBM K6
- [61] Johnson KS, Levin F, Chu DS. Persistent corneal epithelial defect associated with erlotinib treatment. *Cornea* 2009; 28: 706–707 EBM K6
- [62] Magde GE, Geeraets WJ, Guerry III D. Black cornea secondary to topical epinephrine. *Am J Ophthalmol* 1971; 71: 402–405 EBM K6
- [63] McLendon BF, Bron AJ. Corneal toxicity from vinblastine solution. *Br J Ophthalmol* 1978; 62: 97–99 EBM K6
- [64] Lichtinger A, Pe'er J, Frucht-Pery J et al. Limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia. *Ophthalmology* 2010; 117: 431–437 EBM K5
- [65] Liu Y, Yanai R, Lu Y et al. Effects of antiglaucoma drugs on collagen gel contraction mediated by human corneal fibroblasts. *J Glaucoma* 2006; 15: 255–259
- [66] Madreperla SA, Johnson M, O'Brien TP. Corneal endothelial dysfunction in digoxin toxicity. *Am J Ophthalmol* 1992; 113: 211–212 EBM K6
- [67] Mallari PL, McCarty DJ, Daniell M et al. Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. *Am J Ophthalmol* 2001; 131: 131–133 EBM K5
- [68] Masuda I, Matsuo T, Okamoto K et al. Two cases of corneal perforation after oral administration of nonsteroidal anti-inflammatory drugs: oral NSAID-induced corneal damage. *Eur J Ophthalmol* 2010; 20: 454–456 EBM K6
- [69] Mathalone MBR. Eye and skin changes in psychiatric patients treated with chlorpromazine. *Br J Ophthalmol* 1967; 51: 86–93
- [70] McCormick SA, DiBartolomeo AG, Raju VK et al. Ocular chrysiasis. *Ophthalmology* 1985; 92: 1432–1435 EBM K5
- [71] Mietz H, Roters S, Krieglstein GK. Bullous keratopathy as a complication of trabeculectomy with mitomycin C. *Graefes Arch Clin Exp Ophthalmol* 2005; 243: 1284–1287 EBM K6
- [72] Mitra A, Tsesmetzoglou E, McElvanney A. Corneal deposits and topical ofloxacin – the effect of polypharmacy in the management of microbial keratitis. *Eye* 2007; 21: 410–412 EBM K6
- [73] Mohammadpour M, Jabbarvand M, Javadi MA. Focal corneal decompensation after filtering surgery with mitomycin C. *Cornea* 2007; 26: 1285–1287 EBM K6
- [74] Nevyas AS, Raber IM, Eagle RC Jr et al. Acute band keratopathy following intracameral viscoat. *Arch Ophthalmol* 1987; 105: 958–964
- [75] Nishida K, Ohashi Y, Konoshita S et al. Endothelial decompensation in a schizophrenic patient receiving long-term treatment with tranquilizers. *Cornea* 1992; 11: 475–478 EBM K6
- [76] Öhmann L, Wahlberg I. Ocular side-effects of clofazimin. *Lancet* 1975; 2: 933–934 EBM K6
- [77] Orlando RG, Dangel ME, Schaal SF. Clinical experience and grading of amiodarone keratopathy. *Ophthalmology* 1984; 91: 1184–1187 EBM K5
- [78] Oshika T, Itotagawa K, Sawa M. Severe corneal edema after prolonged use of psychotropic agents. *Cornea* 1991; 10: 354–357 EBM K6
- [79] Parkkari M, Paakkala AM, Salminen L et al. Finnish Breast Cancer Group. Ocular side-effects in breast cancer patients treated with tamoxifene and toremifene: a randomized follow-up study. *Acta Ophthalmol Scand* 2003; 81: 495–499 EBM K1
-

-
- [80] Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. *CNS Drugs* 2010; 24: 501–526
- [81] Roberts WH, Wolter JR. Ocular chrysiasis. *Arch Ophthalmol* 1956; 56: 48–52
- [82] Rosenwasser GOD, Holland S, Pflugfelder et al. Topical anesthetic abuse. *Ophthalmology* 1990; 97: 967–972 EBM K6
- [83] Schlote T, Tsamalis A, Kynigopoulos M. Central corneal thickness (CCT) during treatment with travoprost 0.004% in glaucoma patients. *JOPT* 2009; 25: 459–462 EBM K4
- [84] Schlote T, Kellner U. Nebenwirkungen von Medikamenten am Auge. *Klin Monbl Augenheilkd* 2009; 226: R173–R 186
- [85] Seiler K-U, Thiel H-J, Wassermann O. Die Chloroquinkeratopathie als Beispiel einer arzneimittelinduzierten Phospholipidosis (Zugleich ein Beitrag zur Pathogenese der Cornea verticillata). *Klin Monbl Augenheilkd* 1977; 170: 64–73
- [86] Sen E, Nalcacioglu P, Yazici A et al. Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. *J Glaucoma* 2008; 17: 398–402 EBM K4
- [87] Shaw GK, Cantrill HL, Holland EJ. Vortex keratopathy associated with atovaquon. *Am J Ophthalmol* 1995; 120: 669–671 EBM K6
- [88] Shome D, Trent J, Espandar L et al. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. *Ophthalmology* 2008; 115: 483–487 EBM K5
- [89] Solomon A, Frucht-Perry J. Bilateral simultaneous corneal graft rejection after influenza vaccination. *Am J Ophthalmol* 1996; 121: 708–709 EBM K6
- [90] Spinelli D, Vigasio F, Montanari P. Short-term and long-term timolol maleate effects on corneal sensitivity. *Doc Ophthalmol* 1984; 56: 385–392 EBM K4
- [91] Spitzer MS, Szurman P, Aisenbrey S et al. Rapid development of band keratopathy of corneal graft associated with treatment with intracameral recombinant tissue plasminogen activator for postoperative fibrin reaction. *Eur J Ophthalmol* 2007; 17: 433–436 EBM K6
- [92] Steinemann TL, Koffler BH, Jennings CD. Corneal allograft rejection following immunization. *Am J Ophthalmol* 1988; 106: 575–578 EBM K6
- [93] Szymanski A, Gierek-Lapinska A, Koziak M et al. A fluorophotometric study of corneal endothelium after trabeculectomy using different concentrations of mitomycin-c. *Int Ophthalmol* 1997; 20: 95–99 EBM K4
- [94] Taravella MJ, Stulting RD, Mader ThH et al. Calcific band keratopathy associated with the use of topical steroidphosphate preparations. *Arch Ophthalmol* 1994; 112: 608–613 EBM K6
- [95] Toshida H, Uesugi Y, Ebihara N et al. In vivo observations of a case of chlorpromazine deposits in the cornea using an HRT II Rostock corneal module. *Cornea* 2007; 26: 1141–1143 EBM K6
- [96] Ucakhan OO, Kanpolat A, Ylmaz N et al. Amiodarone keratopathy: an in vivo confocal microscopy study. *Eye Contact Lens* 2005; 31: 148–157 EBM K4
- [97] Ullman S, Lichtenstein SB, Heerlein K. Corneal opacities secondary to viscoat. *J Cataract Refract Surg* 1986; 12: 489–492 EBM K6
- [98] Walter K, Tyler ME. Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases. *Cornea* 2006; 25: 855–857 EBM K6
- [99] Wertheim MS, Keel M, Cook SD et al. Corneal transplant rejection following influenza vaccination. *Br J Ophthalmol* 2006; 90: 925 EBM K6
- [100] Wilbanks GA, Apel AJ, Jolly SS et al. Perfluorodecalin corneal toxicity: five case reports. *Cornea* 1996; 15: 329–334 EBM K6
- [101] Williams K, Ilari L. Persistent corneal endothelial deposits associated with rifabutin therapy for Crohn's disease. *Cornea* 2010; 29: 706–707 EBM K6
- [102] Wilson FM. Adverse external ocular effects of topical ophthalmic medications. *Arch Ophthalmol* 1979; 24: 57–88
- [103] Wirtisch MG, Findl O, Kiss B et al. Short-term effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata. *Arch Ophthalmol* 2004; 122: 1089 EBM K1
- [104] Wu KY, Wang HZ, Hong SJ. Effect of latanoprost on cultured porcine corneal stromal cells. *Curr Eye Res* 2005; 30: 871–887
- [105] Yang CS, Chen KH, Hsu WM et al. Cytotoxicity of silicone oil on cultivated human corneal endothelium. *Eye* 2008; 22: 282–288

Kap. 7

- [1] Abdel-Aziz S, Mamalis N. Intraoperative floppy iris syndrome. *Curr Opin Ophthalmol* 2009; 20: 37–41
- [2] Altan-Yaycioglu R, Gedik S, Pelit A et al. Clinical factors associated with floppy iris signs: a prospective study from two centers. *Ophthalmic Surg Lasers Imaging* 2009; 40: 232–238 EBM K4
- [3] Amin K, Fong K, Horgan SE. Incidence of intraoperative floppy iris syndrome in a U.K. district general hospital and implications for future workload. *Surgeon* 2008; 6: 207–209 EBM K4
- [4] Axelsson U. Glaucoma, miotic therapy and cataract. I. The frequency of anterior subcapsular vacuoles in glaucoma eyes treated with echothiophate (Phospholine Iodine), pilocarpine or pilocarpine- eserine, an a nonglaucomatous untreated eyes with common senile cataract. *Acta Ophthalmol Scand* 1968; 46: 83–98 EBM K4
- [5] Bar S, Feller N, Savir H. Presenile cataracts in phenytoin-treated epileptic patients. *Arch Ophthalmol* 1983; 101: 422–425 EBM K6
- [6] Black LR, Oglesby RB, Sallmann von L, Bunim JJ. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. *J Am Med Ass* 1960; 174: 166–171 EBM K6
- [7] Brooks JG, Matoba AY. Chlorpromazine-induced anterior segment changes. *Arch Ophthalmol* 1992; 110: 126 EBM K5
- [8] Calotti F, Steen D. Labetalol causing intraoperative floppy iris syndrome. *J Cataract Refract Surg* 2007; 33: 170–171 EBM K6
- [9] Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. *J Cataract Refract Surg* 2005; 31: 664–673 EBM K5
- [10] Chang DF, Braga-Meie R, Mamalis N et al., ASCRS Cataract Clinical Committee. *J Cataract Refract Surg* 2008; 34: 1201–1209
- [11] Chang DF. Use of Malyugin pupil expansion device for intraoperative floppy iris syndrome: results of 30 consecutive cases. *J Cataract Refract Surg* 2008; 34: 835–841 EBM K5
- [12] Chodick G, Heymann AD, Flash S et al. Persistence with statins and incident cataract: a population-based historical cohort study. *Ann Epidemiol* 2010; 20: 136–142
- [13] Cumming RG, Mitchell P. Medications and cataract. The Blue Mountains Eye Study. *Ophthalmology* 1998; 105: 1751–1758
- [14] Deleu H, Roelandts R. Protecting the eye from ultraviolet A radiation during photochemotherapy. *Photodermatol Photoimmunol Photomed* 1990; 7: 233–236
- [15] Flach AJ, Dolan BJ, Sudduth B, Wedell J. Amiodarone-induced lens opacities. *Arch Ophthalmol* 1983; 101: 1554–1556 EBM K5
- [16] Flach AJ, Dolan BJ. Progression of amiodarone induced cataracts. *Doc Ophthalmol* 1993; 83: 323–329 EBM K5
- [17] Garbe E, Suissa S, LeLorier J. Exposure to allopurinol and the risk of cataract extraction in elderly patients. *Arch Ophthalmol* 1998; 116: 1652–1656
- [18] Gianni L, Panzini I, Li S et al. International Breast Cancer Study Group. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. *Cancer* 2006; 106: 505–513 EBM K3
- [19] Hamming NA, Apple DJ, Goldberg MF. Histopathology and ultrastructure of busulfan-induced cataract. *Graefes Arch Clin Exp Ophthalmol* 1976; 200: 139–147
- [20] Heuberger A, Büchi ER. Irreversible Katarakt als mögliche Nebenwirkung von Isotretinoin. *Klin Monbl Augenheilkd* 1994; 204: 465–467 EBM K6
- [21] Hockwin O, Koch H-R. *Arzneimittelnebenwirkungen am Auge*. Stuttgart: Gustav Fischer Verlag; 1977: 49–82
- [22] Holmström G, Borgström B, Calissendorff B. Cataract in children after bone marrow transplantation: relation to conditioning regimen. *Acta Ophthalmol Scand* 2002; 80: 211–215 EBM K4
- [23] Ikäheimo K, Kettunen R, Mäntyjärvi M. Visual function and adverse ocular effects in patients with amiodarone medication. *Acta Ophthalmol Scand* 2002; 80: 59–63 EBM K5
- [24] Imperia PS, Lazarus HM, Lass JH. Ocular complications of systemic cancer chemotherapy. *Surv Ophthalmol* 1989; 34: 209–230
- [25] Issa SA, Dagres E. Intraoperative floppy-iris syndrome and finasteride intake. *J Cataract Refract Surg* 2007; 33: 2142–2143 EBM K6

-
- [26] James ER. The etiology of steroid cataract. *J Ocul Pharmacol Ther* 2007; 23: 403–420
- [27] Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. *Acta Ophthalmol Scand* 2005; 83: 645–663
- [28] Jones DF, Irwin AE. Discoloration of intraocular lens subsequent to rifabutin use. *Arch Ophthalmol* 2002; 120: 1211–1212 EBM K6
- [29] Jose JG, Koch HR, Respondek A. Histologic observations of the lenses of Psoralen + UVA treated albino rats and a theory as to the underlying mechanism. *Graefes Arch Clin Exp Ophthalmol* 1982; 219: 44–53
- [30] Kanthan GL, Wang JJ, Rochtchina E et al. Use of antihypertensive medications and topical beta-blockers and the long-term incidence of cataract and cataract surgery. *Br J Ophthalmol* 2009; 93: 1210–1214 EBM K4
- [31] Kanthan GL, Wang JJ, Burlutsky G et al. Exogenous oestrogen exposure, female reproductive factors and the long-term incidence of cataract: the Blue Mountains Eye Study. *Acta Ophthalmol* 2010; 88: 773–778 EBM K4
- [32] Lerman S, Megaw J, Fraunfelder FT. Further studies on allopurinol therapy and human cataractogenesis. *Am J Ophthalmol* 1984; 97: 205–209
- [33] Lindblad BE, Håkansson N, Philipson B et al. Hormone replacement therapy in relation to risk of cataract extraction: a prospective study of women. *Ophthalmology* 2010; 117: 424–430 EBM K4
- [34] Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25 year prospective study. *J Am Acad Dermatol* 2007; 57: 231–237 EBM K4
- [35] Mathalone MBR. Eye and skin changes in psychiatric patients treated with chlorpromazine. *Br J Ophthalmol* 1967; 51: 86–93 EBM K5
- [36] McCormick SA, DiBartolomeo AG, Raju VK et al. Ocular chrysiasis. *Ophthalmology* 1985; 92: 1432–1435 EBM K5
- [37] Michon Jr J, Kinoshita JH. Experimental miotic cataract. I. Effect of miotics on lens structure, cation content, and hydration. *Arch Ophthalmol* 1968; 79: 79–86
- [38] Neff KD, Sandoval HP, Fernandez de Castro LE et al. Factors associated with intraoperative floppy iris syndrome. *Ophthalmology* 2009; 116: 658–663 EBM K4
- [39] Parkkari M, Paakkala AM, Salminen L et al. Ocular side effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. *Acta Ophthalmol Scand* 2003; 81: 495–499 EBM K4
- [40] Razeghinejad MR, Nowroozzadeh MH, Zamani M et al. In vivo observations of chlorpromazine ocular deposits in a patient on long-term chlorpromazine therapy. *Clin Experiment Ophthalmol* 2008; 36: 560–563 EBM K6
- [41] Robertson DG, Urda ER, Rothwell CE et al. Atorvastatin is not cataractogenic in beagle dogs. *Curr Eye Res* 1997; 16: 1229–1235
- [42] Savir H, Bar S, Feller N. Presenile cataracts in hydantoin-treated epileptic patients. *Metab Pediatr Syst Ophthalmol* 1983; 7: 169–171 EBM K6
- [43] Schaal S, Beiran I, Rozner I et al. Desferrioxamine and zinc-desferrioxamine reduce lens oxidative damage. *Exp Eye Res* 2007; 84: 561–568
- [44] Schrader KE. Linsentrübungen nach Pantocain-Applikation. *Klin Monbl Augenheilkd* 1962; 140: 287–290 EBM K6
- [45] Smeeth L, Hubbard R, Fletcher AE. Cataract and the use of statins: a case-control study. *QJM* 2003; 96: 337–343
- [46] Spoto G, Mastropasqua L, Gizzi F et al. Hypoxanthine and xanthine levels in human aqueous humor from cataractogenous eyes. *Life Science* 1996; 59: PL 387–390
- [47] Stern RS. Ocular lens findings in patients treated with PUVA. Photochemotherapy follow-up study. *J Invest Dermatol* 1994; 103: 534–538 EBM K5
- [48] Stevens S, Werner L, Mmalis N. Corneal edema and permanent blue discoloration of a silicone intraocular lens by methylene blue. *Ophthalmic Surg Lasers Imaging* 2007; 38: 136–141 EBM K6
- [49] Tan JS, Mitchell P, Rochtchina E et al. Statin use and the long-term risk of incident cataract: the Blue Mountains Eye Study. *Am J Ophthalmol* 2007; 143: 687–689
- [50] Taneja R, Malik P, Sharma M et al. Multiple transfused thalassemia major: ocular manifestations in a hospital-based population. *Indian J Ophthalmol* 2010; 58: 125–130 EBM K5
- [51] Unal M, Yucel I, Tenlik A. Intraoperative floppy-iris syndrome associated with chronic use of chlorpromazine. *Eye* 2007; 21: 1241–1242 EBM K6
- [52] Urban RC, Cotlier E. Corticosteroid-induced cataracts. *Surv Ophthalmol* 1986; 31: 102–110

-
- [53] Weatherall M, Clay J, James K et al. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. *Respirology* 2009; 14: 983–990
- [54] Werner L, Apple DJ, Crema AS et al. Permanent blue discoloration of a hydrogel intraocular lens by intraoperative trypan blue. *J Cataract Refract Surg* 2002; 28: 1279–1286 EBM K6
- [55] Werner L. Causes of intraocular lens opacification or discoloration. *J Cataract Refract Surg* 2007; 33: 713–726
- [56] Younan C, Mitchell P, Cumming R et al. Cardiovascular disease, vascular risk factors and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study. *Ophthalmic Epidemiol* 2003; 10: 227–240
- [57] Zakrzewski P, Milewska J, Czerny K. The eye lens evaluation of the atorvastatin-treated white rat. *Ann Univ Mariae Curie Sklodowska Med* 2002; 57: 165–171

Kap. 8

- [1] Ahmad S. Disopyramide: pulmonary complications and glaucoma. *Mayo Clin Proc* 1990; 65: 1030–1031 EBM K6
- [2] Ahmed S. Fluoxetine and glaucoma. *Ann Pharmacother* 1991; 25: 436
- [3] Assia El Raskin T, Kaiserman I et al. Effect of aspirin intake on bleeding during cataract surgery. *J Cataract Refract Surg* 1998; 24: 1243–1246 EBM K3
- [4] Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. *Ophthalmic Surg Lasers Imaging* 2003; 34: 43486–43390 EBM K5
- [5] Bard LA. Transient myopia associated with promethazine (Phenergan) therapy: report of a case. *Am J Ophthalmol* 1964: 682 EBM K6
- [6] Bennett HG, Wyllie AM. Paroxetine and acute angle-closure glaucoma. *Eye* 1999; 13: 691–692 EBM K6
- [7] Brath PC, MacGregor DA, Ford JG et al. Dopamine and intraocular pressure in critically ill patients. *Anesthesiology* 2000; 93: 1398–1400 EBM K4
- [8] Budd J, Hardwick M, Barber K et al. A single-centre study of 1000 consecutive peribulbar blocks 2001; 15: 464–468 EBM K4
- [9] Chang WJ, Nowinski TS, Repke CS et al. Spontaneous orbital hemorrhage in pregnant woman treated with subcutaneous heparin. *Am J Ophthalmol* 1996; 122: 907–908 EBM K6
- [10] Chorich LJ, Derick RJ, Chambers et al. Hemorrhagic ocular complications associated with the use of systemic thrombolytic agents. *Ophthalmology* 1998; 105: 428–431 EBM K6
- [11] Costagliola C, Mastropasqua L, Steardo L et al. Fluoxetine oral administration increases intraocular pressure. *Br J Ophthalmol* 1996; 80: 678
- [12] Crawford JS, Lewandowski RL, Chan W. The effect of aspirin on rebleeding in traumatic hyphema. *Am J Ophthalmol* 1975; 80: 543–545 EBM K5
- [13] Crouch ER jr, Crouch ER. Management of traumatic hyphema: therapeutic options. *J Pediatric Ophthalmol Strabismus* 1999; 36: 238–250
- [14] Davidson SI. Reports of ocular adverse reactions. *Trans Ophthalmol Soc UK* 1973; 93: 495–510
- [15] Dobrilla G, Felder M, Chiloni F et al. Exacerbation of glaucoma associated with both cimetidine and ranitidine. *Lancet* 1982; 1: 1078 EBM K6
- [16] Eke T, Carr S. Acute glaucoma, chronic glaucoma, and serotonergic drugs. *Br J Ophthalmol* 1998; 82: 976–978 EBM K6
- [17] Eke T, Bates AK. Acute angle closure glaucoma associated with paroxetine. *BMJ* 1997; 314: 1387 EBM K6
- [18] Epstein NE, Goldbloom DS. Oral imipramine and acute angle closure glaucoma. *Arch Ophthalmol* 1995; 113: 698 EBM K6
- [19] El Baba F, Jarrett WH 2nd, Harbin TS jr et al. Massive hemorrhage complicating age related macular degeneration. *Ophthalmology* 1986; 93: 1581–1592
- [20] Eltzschig HK, Darsow R, Schroeder TH et al. Effect of tracheal intubation or laryngeal mask airway insertion on intraocular pressure using balanced anesthesia with sevoflurane and remifentanyl. *J Clin Anesth* 2001; 13: 264–267 EBM K3
- [21] Feldman F, Cohen MM. Effects of histamine-2 receptor blockade by cimetidine on intraocular pressure in humans. *Am J Ophthalmol* 1982; 93: 351 EBM K4

-
- [22] Fraunfelder FT. Drug induced ocular side effects. 4th ed. Baltimore: Williams & Wilkins; 1996: 203–204
- [23] François J, Goes F. Ultrasonographic study of the effect of different miotics on the eye components. *Ophthalmologica* 1977; 175: 328–338
- [24] Garbe E, LeLorier J, Bovin JF et al. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. *Lancet* 1997; 350: 979–982
- [25] Clark AF, Wilson K, McCartney MD et al. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. *Invest Ophthalmol Vis Sci* 1994; 35: 281–294
- [26] Greenfield DS, Liebmann JM, Ritch R et al. Hyphema associated with pupillary dilatation in a patient with exfoliation glaucoma and warfarin therapy. *Am J Ophthalmol* 1999; 128: 98–100 EBM K6
- [27] Harris LS. Cycloplegic-induced intraocular pressure elevations. *Arch Ophthalmol* 1968; 79: 242–246
- [28] Herndon LW, Asrani SG, Williams GH et al. Paradoxical intraocular pressure elevation after combined therapy with Latanoprost and Bimatoprost. *Arch Ophthalmol* 2002; 120: 847–849 EBM K6
- [29] Hutcheson KA. Steroid-induced glaucoma in an infant. *J AAPOS* 2007; 11: 522–523 EBM K6
- [30] Jay WM, Carter H, Williams B et al. Effect of applying the Honan intraocular pressure reducer before cataract surgery. *Am J Ophthalmol* 1985; 100: 523–527 EBM K4
- [31] Johnson D, Gottanka J, Flügel C et al. Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. *Arch Ophthalmol* 1997; 11: 375–383
- [32] Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injections of triamcinolon acetonide. *Br J Ophthalmol* 2003; 87: 8724–8727 EBM K4
- [33] Jones R, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. *Curr Opin Ophthalmol* 2006; 17: 163–168
- [34] Kass M, Cheetham J, Duzman E et al. The ocular hypertensive effect of 0.25% fluorometholone in corticosteroid responders. *Am J Ophthalmol* 1986; 102: 159–163 EBM K1
- [35] Katsushima H. Corticosteroid-induced glaucoma following treatment of the periorbital region. *Nippon-Ganka-Gakkai-Zasshi* 1995; 99: 238–243 EBM K6
- [36] Kaul RL, Mehta S, Jain GC et al. A case of acute congestive glaucoma probably induced by imipramine. *J Assoc Physicians India* 1981; 29: 63–64 EBM K6
- [37] Kent AR, Vroman DT, Thomas TJ et al. Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension. *J Glaucoma* 1999; 8: 257–262
- [38] Kitazawa Y. Increased intraocular pressure induced by corticosteroids. *Am J Ophthalmol* 1976; 82: 492–495 EBM K4
- [39] Kinek M. Glaucoma following the antidepressant mianserin. *Harefuah* 1990; 118: 699–700 EBM K6
- [40] Kohler MP, Sholiton DB. Spontaneous hyphema resulting from warfarin. *Ann Ophthalmol* 1983; 15: 858–859 EBM K6
- [41] Lanini PG, Simona FS. Intraokulare Druckveränderungen nach peribulbärer und retrobulbärer Injektion: praktische Folgen. *Klin Monbl Augenheilkd* 1998; 212: 283–285 EBM K4
- [42] Leibmann J, Spaeth GL. Primary angle-closure glaucoma. In: Eid TM, Spaeth GL, eds. *The glaucomas. Concepts and Fundamentals*. Baltimore: Lippincott Williams & Wilkins; 2000: 125–137
- [43] Leibowitz HM, Bartlett JD, Rich R et al. Intraocular pressure-raising potential of 1,0% Rimexolone in patients responding to corticosteroids. *Arch Ophthalmol* 1996; 114: 933–937 EBM K1
- [44] Lewis CF, DeQuardo JR, DuBose C. Acute angle-closure glaucoma and paroxetine. *J Clin Psychiatry* 1997; 58: 123–124 EBM K6
- [45] Lowe RF. Amitryptiline and glaucoma. *Med J Aust* 1966; 2: 509–510 EBM K6
- [46] Lütjen-Drecoll E, May CA, Polansky JR et al. Localization of the stress proteins α B-Crystallin and trabecular meeshwork inducible glucocorticoid response protein in normal and glaucomatous trabecular meshwork. *Invest Ophthalmol Vis Sci* 1998; 39: 517–525
- [47] Mapstone R. Dilating dangerous pupils. *Br J Ophthalmol* 1977; 61: 517–524
- [48] Mitchell P, Cumming RG, Mackey DA. Inhaled corticosteroids, family history, and risk factor of glaucoma. *Ophthalmology* 1999; 106: 2301–2306
- [49] Morgan JE, Chanda A. Intraocular pressure after peribulbar anesthesia: is the Honan balloon necessary? *Br J Ophthalmol* 1993; 100: 46–49 EBM K4
-

-
- [50] Ness T, Funk J. Increase of intraocular pressure after topical administration of prostaglandin analogs. *Arch Ophthalmol* 1999; 117: 1646–1647 EBM K6
- [51] O'Donoghue E, Batterbury M, Lavy T. Effect of local anaesthesia in eyes undergoing intraocular surgery. *Br J Ophthalmol* 1994; 78: 605–607 EBM K4
- [52] Pandit RJ, Taylor R. Mydriasis and glaucoma: exploding the myth. A systematic review. *Diabet Med* 2000; 17: 693–699
- [53] Patel KH, Javitt JC, Tielsch JM et al. Incidence of acute angle-closure glaucoma after pharmacologic mydriasis. *Am J Ophthalmol* 1995; 120: 709–717
- [54] Piltz JR, Stone RA, Boike S et al. Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure. *J Ocul Pharmacol Ther* 1998; 14: 203–216 EBM K1
- [55] Rhee DJ, Peck RE, Bekmont J et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. *Br J Ophthalmol* 2006; 90: 999–1003 EBM K5
- [56] Ritch R, Krupin T, Henry C et al. Oral imipramine and acute angle closure glaucoma. *Arch Ophthalmol* 1994; 112: 67–68 EBM K6
- [57] Rubin B, Taglienti A, Rothman RF et al. The effect of selective laser trabeculoplasty on intraocular pressure in patients with intravitreal steroid-induced elevated intraocular pressure. *J Glaucoma* 2008; 17: 287–292
- [58] Rotenstreich Y, Robowitz A, Segev F et al. Effect of warfarin therapy on bleeding during cataract surgery. *J Cataract Refract Surg* 2001; 27: 1344–1346
- [59] Sampat KM, Garg SJ. Complications of intravitreal injections. *Curr Opin Ophthalmol* 2010; 21: 178–183
- [60] Schlote T, Freudenthaler N, Gelisken F. Akutes Winkelblockglaukom nach massiver intraokularer Blutung bei exsudativer altersbedingter Makuladegeneration unter gerinnungshemmender Therapie. *Ophthalmologe* 2005; 102: 1090–1096 EBM K5
- [61] Scholl HPN, Thiel HJ, Schlote T. Orbitablutung als Folge einer heparininduzierten Thrombozytopenie. *Klin Monbl Augenheilkd* 1999; 215: 197–200 EBM K6
- [62] Shields MB, Krieglstein GK, Hrsg. *Glaukom: Grundlagen, Differentialdiagnose, Therapie*. Berlin: Springer; 1993: 358–361
- [63] Steinemann T, Goins K, Smith T et al. Acute closed-angle glaucoma complicating hemorrhagic choroidal detachment associated with parenteral thrombolytic agents. *Am J Ophthalmol* 1988; 106: 752–753 EBM K6
- [64] Stevens J, Giubilei M, Lanigan L et al. Sub-tenon, retrobulbar, and peribulbar local anesthesia: the effect upon intraocular pressure. *Eur J Implant Ref Surg* 1993; 5: 25–28
- [65] Stone EM, Fingert JH, Alward WLM et al. Identification of a gene that causes primary open angle glaucoma. *Science* 1997; 275: 668–670
- [66] Tripathi RC, Parapuram SK, Tripathi BJ et al. Corticosteroids and glaucoma risk. *Drugs Aging* 1999; 15: 439–450
- [67] Trope GE, Hind VM. Closed-angle glaucoma in patient on disopyramide. *Lancet* 1978; 1: 329 EBM K6
- [68] Weijtens O, van der Sluijs FA, Schoemaker RC et al. Peribulbar corticoid injection: vitreal and serum concentration after dexamethasone disodium phosphate injection. *Am J Ophthalmol* 1997; 123: 358–363 EBM K4
- [69] Weijtens O, Feron EJ, Schoemaker RC et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. *Am J Ophthalmol* 1999; 128: 192–197 EBM K4
- [70] Wingate RJ, Beaumont PE. Intravitreal triamcinolon an elevated intraocular pressure. *Aust N Z J Ophthal* 1999; 27: 27431–27432 EBM K4
- [71] Wolfs RCW, Grobbee DE, Hofman A et al. Risk of acute angle-closure glaucoma after diagnostic mydriasis in nonselected subjects: the Rotterdam study. *Invest Ophthalmol Vis Sci* 1997; 38: 2683–2687

Kap. 9

- [1] Aiai N, Dolan JW, Kacere RD et al. The effect on aqueous dynamics of PhX4A41, a new prostaglandin analogue after topical application in normal and ocular hypertensive human eyes. *Arch Ophthalmol* 1993; 111: 1351–1358
- [2] Akingbehin T, Villada J. Metipranolol-associated granulomatous anterior uveitis. *Br J Ophthalmol* 1991; 75: 519–523
- [3] Alm A, Grierson I, Shields B. Side effects associated with prostaglandin analog therapy. *Surv Ophthalmol* 2008; 53 (Suppl.): S 93–S 105
- [4] Alm A, Villumsen J. PhXA34, a new potent ocular hypotensive drug. *Arch Ophthalmol* 1991; 109: 1564–1568 EBM K2

-
- [5] Ambati J, Wynne KB, Angerame MC et al. Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. *Br J Ophthalmol* 1999; 83: 1153–1158 EBM K5
- [6] Bainbridge JW, Raina J, Shah SM et al. Ocular complications of intravenous cidofovir for cytomegalovirus retinitis in patients with AIDS. *Eye* 1999; 13: 353–356 EBM K5
- [7] Beck AD, Wilson WR, Lynch MG et al. Trabeculectomy with adjunctive Mitomycin C in pediatric glaucoma. *Am J Ophthalmol* 1998; 126: 648–657 EBM K5
- [8] Becker H, Walton RC, Diamant JI et al. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. *Arch Ophthalmol* 2004; 122: 1063–1066 EBM K6
- [9] Blumberg S, Bienfang D, Kantrowitz FG. A possible association between influenza vaccination and small vessel vasculitis. *Arch Intern Med* 1980; 140: 847–848 EBM K6
- [10] Byles DB, Frith P, Salmon JF. Anterior uveitis as a side effect of topical brimonidine. *Am J Ophthalmol* 2000; 130: 287–291 EBM K6
- [11] Camras CB, Neely DG, Weiss EL. Latanoprost-induced iris color darkening: a case report with long-term follow-up. *J Glaucoma* 2000; 9: 95–98 EBM K6
- [12] Chang JH, McClusky P, Missotten T et al. Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema? *Br J Ophthalmol* 2008; 92: 916–921 EBM K5
- [13] Chaves-de la Paz E, Arevalo JF, Kirsch LS et al. Anterior nongranulomatous uveitis after intravitreal HPMP (cidofovir) for the treatment of cytomegalovirus retinitis. *Ophthalmology* 1997; 104: 539–544 EBM K4
- [14] Chiba T, Kashiwagi K, Kogure S et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. *J Glaucoma* 2001; 10: 406–410 EBM K2
- [15] Costa VP, Wilson RP, Moster MR et al. Hypotony maculopathy following the use of topical Mitomycin C in glaucoma filtration surgery. *Ophthalm Surg* 1993; 24: 289–394 EBM K6
- [16] Davidson SI. Reported adverse effects of oral contraceptives on the eye. *Trans Ophthalmol Soc UK* 1971; 91: 561–574 EBM K6
- [17] Davis JL, Taskintuna I, Freeman WR et al. Iris and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. *Arch Ophthalmol* 1997; 115: 733–737 EBM K5
- [18] Deuter CME, Zierhut M, Möhle A et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet's disease. *Arthritis & Rheumatism* 2010; 62: 2796–2805
- [19] Diestelhost M, Roters S, Kriegelstein G. The effects of latanoprost (PhXA41) on the intraocular pressure and aqueous humor protein concentration: a randomized, double masked comparison of 50 mg/ml vs. 15 mg/ml with timolol 0.5% as control. *ARVO abstracts. Invest Ophthalmol Vis Sci* 1995; 36: 823
- [20] Doherty MD, Wride NK, Birch et al. Choroidal detachment in association with topical dorzolamide: is hypotony always the cause? *Clin Experiment Ophthalmol* 2009; 37: 750–752 EBM K6
- [21] Donaldson RC, Canaan SAJ, McLean RB et al. Uveitis and vitiligo associated with BCG treatment for malignant melanoma. *Surgery* 1974; 76: 771–778 EBM K6
- [22] Doycheva D, Deuter C, Stuebiger N et al. Interferon-alpha-associated presumed ocular sarcoidosis. *Graefes Arch Clin Exp Ophthalmol* 2009; 247: 675–680 EBM K6
- [23] Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. *Exp Eye Res* 2000; 70: 563–569
- [24] Faus S, Martinez Montauti JM, Puig L. Reiter's syndrome after administration of intravesical bacille Calmette-Guérin (letter). *Clin Infect Dis* 1993; 17: 526–527 EBM K6
- [25] Fechtner RD, Khouri AS, Zimmerman TJ et al. Anterior uveitis associated with latanoprost. *Am J Ophthalmol* 1998; 126: 37–41 EBM K6
- [26] Fischer R, Henkind P, Gartner S. Microcysts of the human iris pigment epithelium. *Br J Ophthalmol* 1979; 63: 750–753 EBM K4
- [27] Fraunfelder FT. Drug induced ocular side effects, 4th ed. Baltimore: Williams & Wilkins, 1996 (Diethylcarbamazine: 7–8, Chinin: 63–65, Mitomycin C: 349–352, Pilocarpin: 451–456, Neostigmin: 450–451, Epinephrin: 275–278, Echothiophate: 447–450, Kortison: 284–293)
- [28] Fuller JD, Stanfield LE, Craven DE. Rifabutin prophylaxis and uveitis (letter). *N Engl J Med* 1994; 330: 1315–1316
- [29] Goldberg S, Gallily R, Bishara S et al. Dorzolamide-induced choroidal detachment in a surgically untreated eye. *Am J Ophthalmol* 2004; 138: 285–286 EBM K6
-

-
- [30] Goyal R, Ram AR. Brimonidine tartrate 0.2% (Alphagan) associated granulomatous anterior uveitis. *Eye* 2000; 14: 908–910 EBM K6
- [31] Greenfield DS, Suner IJ, Miller MP et al. Endophthalmitis after filtering surgery with Mitomycin. *Arch Ophthalmol* 1996; 114: 943–949 EBM K5
- [32] Havlir D, Torriani F, Dube M. Uveitis associated with rifabutin prophylaxis. *Ann Intern Med* 1994; 121: 510–512 EBM K6
- [33] Hirano A, Kataoka M, Nakata Y et al. Sarcoidosis occurring after interferon-alpha therapy for chronic hepatitis C: report of two cases. *Respirology* 2005; 10: 529–534 EBM K6
- [34] Hotehama Y, Mishima HK. Clinical efficacy of PhA34 and PhXA41, two novel prostaglandin F2a-isopropyl ester analogues for glaucoma treatment. *Jpn J Ophthalmol* 1993; 37: 259–269 EBM K2
- [35] Huang P, Zhomng Z, Wu L et al. Increased iridal pigmentation in Chinese eyes after use of travoprost 0.004%. *J Glaucoma* 2009; 18: 153–156 EBM K2
- [36] Husted JD. Granulomatous uveitis and quinidine hypersensitivity. *Am J Ophthalmol* 1991; 112: 461–462 EBM K6
- [37] Kay JS, Simons KB, Chvapil M. Sub-tenon delivery of 5-fluorouracil/collagen sponge implants in the rabbit. *Glaucoma* 1991; 13: 51
- [38] Kerstetter JR, Brubaker RF, Wilson SE et al. Prostaglandin-F2a-1-isopropyl ester lowers intraocular pressure without decreasing aqueous humor flow. *Am J Ophthalmol* 1988; 105: 30–34 EBM K2
- [39] Kirsch LS, Arevalo JF, DeClercq E et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patient with the acquired immunodeficiency syndrome. *Am J Ophthalmol* 1995; 119: 466–476 EBM K3
- [40] Knopf HLS. Recurrent uveitis after influenza vaccination. *Ann Ophthalmol* 1991; 23: 213–214 EBM K6
- [41] Knopf HLS, Wexler SA. Recurrent uveitis following influenza vaccination. *Ophthalmic Practice* 1996; 14: 21–24 EBM K6
- [42] Knox DL, Palmer CAL, English F. Iris atrophy after quinine amblyopia. *Arch Ophthalmol* 1966; 76: 359–362 EBM K6
- [43] Krohne J, Hove VK. Iris cyst associated with topical administration of latanoprost. *Am J Ophthalmol* 1999; 127: 91–93 EBM K6
- [44] Krupin T, LeBlanc RP, Becker B et al. Uveitis in association with topically administered corticosteroid. *Am J Ophthalmol* 1970; 70: 883–885 EBM K5
- [45] Lee B, Turner WM. Food and drug administration's adverse drug reaction monitoring program. *Am J Hosp Pharm* 1978; 35: 929–932
- [46] Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? *Arthritis & Rheumatism* 2007; 56: 3248–3252 EBM K5
- [47] Lindquist NG, Larsson BS, Stjernschantz J. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue. *Exp. Eye Res* 1999; 69: 431–436
- [48] Lish A, Berman DH. Tuberculin-triggered panuveitis in a patient recently treated for active pulmonary tuberculosis. *Am J Ophthalmol* 1993; 116: 771–773 EBM K6
- [49] Lopez V, Sola E, Gutierrez C et al. Anterior uveitis associated with treatment with intravenous cidofovir in kidney transplant patients with BK virus nephropathy. *Transplant Proc* 2006; 38: 2412–2413 EBM K6
- [50] Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. *Am J Ophthalmol* 1994; 118: 220–224 EBM K5
- [51] Martins JC, Wilensky JT, Asseff CF et al. Corticosteroid-induced uveitis. *Am J Ophthalmol* 1974; 77: 433–437 EBM K5
- [52] Mathe G, Amiel JL, Schwarzenberg L et al. Active immunotherapy for acute lymphoblastic leukemia. *Lancet* 1969; 1: 697–699 EBM K6
- [53] Moorthy RS, Valluri S, Jampol LM. Drug-induced uveitis. *Surv Ophthalmol* 1998; 42: 557–570
- [54] Morton BL, Eilber FR, Holmes EC et al. BCG immunotherapy for malignant melanoma: summary of a seven-year-experience. *Ann Surg* 1974; 180: 635–643 EBM K4
- [55] Nguyen EV, Azap D, Papalkar D et al. Brimonidine-induced anterior uveitis and conjunctivitis: clinical and histological feature. *J Glaucoma* 2008; 17: 40–42 EBM K6
- [56] Nichols CW. Mycobacterium avium complex Infection. Rifabutin and Uveitis – Is there a connection? *Clin Infect Dis* 1996; 22: 43–49
- [57] Nightingale SD, Cameron DW, Gordin FM et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. *N Engl J Med* 1993; 329: 828–833 EBM K1
-

-
- [58] Nussenblatt RB, Palestine AG. Uveitis fundamentals and practice. Chicago: Yearbook Medical Publishers; 1989: 288
- [59] O'Donnel NP, Rao GP, Aguis-Fernandez A. Paget's disease: ocular complications of disodium pamidronate treatment. *Br J Clin Pract* 1995; 49: 272–273 EBM K6
- [60] Ophir A, Ticho U. Remission of anterior uveitis by subconjunctival 5 fluorouracil (correspondence). *Arch Ophthalmol* 1991; 108: 12
- [61] Pancaldi P, Van Linthoudt D, Alborino D et al. Reiter's syndrome after intravesical Bacillus Calmette-Guérin treatment for superficial bladder carcinoma. *Br J Rheumatol* 1993; 32: 1096–1098 EBM K6
- [62] Price GE. Arthritis and iritis after BCG therapy for bladder cancer. *J Rheumatol* 1994; 21: 564–565 EBM K6
- [63] Radnot M, Follmann P. Ocular side-effects of oral contraceptives. *Ann Clin Res* 1973; 5: 197–204 EBM K6
- [64] Ramos-Casals M, Mana J, Nardi N et al. Sarcoidosis in patients with chronic hepatitis C virus infection. Analysis of 68 cases. *Medicine* 2005; 84: 69–80
- [65] Roth DB, Chieh J, Spirn MJ et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. *Arch Ophthalmol* 2003; 121: 1279–1282 EBM K6
- [66] Saran BR, Maguire AM, Nichols C et al. Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. *Arch Ophthalmol* 1994; 112: 1159–1165 EBM K6
- [67] Saurenmann RK, Levin AV, Feldman BM et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNF α agents. *J Pediatr* 2006; 149: 833–836 EBM K6
- [68] Schlote T, Zierhut M. Ocular hypertension and glaucoma associated with scleritis and uveitis. *Dev Ophthalmol* 1999; 30: 91–109
- [69] Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. *Rheumatology* 2005; 44: 1008–1011 EBM K5
- [70] Shafran SD, Deschenes J, Miller M et al. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. *N Engl J Med* 1994; 330: 438–439 EBM K1
- [71] Sharma T, Salmon JF. Hypotony and choroidal detachment as a complication of topical combined timolol and dorzolamide. *J Ocul Pharmacol Ther* 2007; 23: 202–205 EBM K6
- [72] Siris ES. Bisphosphonates and iritis. *Lancet* 1993; 341: 436 EBM K6
- [73] Smith SL, Pruitt CA, Sine CS et al. Latanoprost 0.005% and anterior segment uveitis. *Acta Ophthalmol Scand* 1999; 77: 668–672 EBM K5
- [74] Spitzberg DH. Acute anterior uveitis secondary to quinidine sensitivity. *Arch Ophthalmol* 1979; 97: 1993 EBM K6
- [75] Stjernschantz JW, Albert DM, Hu DN et al. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. *Surv Ophthalmol* 2002; 47 (Suppl. 1): S 162–175
- [76] Sutter FK, Gilies MC. Pseudo-endophthalmitis after intravitreal triamcinolone acetonide injection for cystoid macular edema. *Am J Ophthalmol* 2004; 138: 489–492 EBM K6
- [77] Ticho U, Ophir A. Regulating the dose of 5-fluorouracil to prevent filtering bleb scarring. *Ann Ophthalmol* 1991; 23: 225 EBM K4
- [78] Tilden ME, Rosenbaum JT, Fraunfelder FT. Systemic sulfonamides as a cause of bilateral, anterior uveitis. *Arch Ophthalmol* 1991; 109: 67–69 EBM K6
- [79] Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 α analog, on aqueous humor dynamics in human eyes. *Ophthalmology* 1993; 100: 1297–1304 EBM K1
- [80] Walsh FB, Clark DB, Thompson RS et al. Oral contraceptives and neuro-ophthalmic interest. *Arch Ophthalmol* 1965; 74: 628–640 EBM K6
- [81] Walsh PM, Stark WJ, Johnson MA et al. Use of 5-fluorouracil to prevent posterior capsule opacification. ARVO abstracts. Supplement to Invest Ophthalmol Vis Sci. Philadelphia: JB Lippincott; 1985: 191
- [82] Wang LC, Yang CM. Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide. *Ocul Immunol Inflamm* 2005; 13: 295–300 EBM K5
- [83] Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. *Ophthalmology* 1998; 105: 263–268 EBM K5
- [84] Warwar RE, Bullock JD, Dayton OH. Latanoprost-induced uveitis. *Surv Ophthalmol* 1999; 43: 466
- [85] Weinreb RN. Adjusting the dose of 5-fluorouracil after filtration surgery to minimize side effects. *Ophthalmology* 1987;

94: 564 EBM K4

- [86] Yan KK, Dininhan I, Freiman J et al. Sarcoidosis presenting with granulomatous uveitis induced by pegylated interferon and ribavirin therapy for hepatitis C. *Intern Med J* 2008; 38: 207–210 EBM K6
- [87] Zhan GL, Toris CB, Camras CB et al. Prostaglandin-induced iris color darkening. An experimental model. *Arch Ophthalmol* 1998; 116: 1065–1068
- [88] Ziai N, Dolan J, Kacere R et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F analogue, after topical application in normal and ocular hypertensive human eyes. *Arch Ophthalmol* 1993; 111: 1351–1358 EBM K2

Kap. 10

- [1] Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. *Surv Ophthalmol* 2008; 53 (Suppl. 1): S 93–105 EBM K6
- [2] Baath JS, Lam WC, Kirby M et al. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population. *Retina* 2008; 28: 894–899 EBM K4
- [3] Baldinger J, Dofb BH, Burns SA et al. Retinal toxicity of amphotericin B in vitrectomised versus non-vitrectomised eyes. *Br J Ophthalmol* 1986; 70: 657–661 EBM K6
- [4] Baba T, Kubota-Taniai M, Kitahashi M et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. *Br J Ophthalmol* 2010; 94: 864–870 EBM K3
- [5] Beasley H, Fraunfelder FT. Retinal detachments and topical ocular miotics. *Ophthalmology* 1979; 86: 95–98 EBM K6
- [6] Bernstein HN, Ginsberg J. The pathology of chloroquine retinopathy. *Arch Ophthalmol* 1964; 71: 238–245 EBM K6
- [7] Bishop RJ, Ding X, Heller CK 3rd et al. Rapid vision loss associated with fludarabine administration. *Retina* 2010; 30: 1272–1277
- [8] Borodoker N, Del Priore LV, De A Carvalho C et al. Retinopathy as a result of long-term use of thioridazine. *Arch Ophthalmol* 2002; 120: 994–995 EBM K6
- [9] Borovik AM, Bosch MM, Watson SL. Ocular pigmentation associated with clozapine. *Med J Aust* 2009; 190: 210–211 EBM K6
- [10] Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. *Surv Ophthalmol* 2002; 47: 431–448
- [11] Cardascia N, Boscia F, Furino C et al. Gentamicin-induced macular infarction in transconjunctival sutureless 25-gauge vitrectomy. *Int Ophthalmol* 2008; 28: 383–385 EBM K6
- [12] Chan A, Ko TH, Duker JS. Ultrahigh-resolution optical coherence tomography of canthaxanthine retinal crystals. *Ophthalmic Surg Lasers Imaging* 2006; 37: 138–139 EBM K6
- [13] Classé JG. Epinephrine maculopathy. *J Am Optom Assoc* 1980; 51: 1091–1093 EBM K6
- [14] Cortin P, Corriveau LA, Rousseau AP et al. Maculopathy with golden particles. *Can J Ophthalmol* 1982; 17: 103–106 EBM K6
- [15] Daicker B, Schiedt K, Adnet JJ et al. Canthaxanthin retinopathy. An investigation by light and electron microscopy and physicochemical analysis. *Graefes Arch Clin Exp Ophthalmol* 1987; 225: 189–197 EBM K6
- [16] Davies SC, Marcus RE, Hungerford JL et al. Ocular toxicity of high-dose intravenous desferrioxamine. *Lancet* 1983; 2: 181–184 EBM K6
- [17] Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. *BMJ* 1997; 314: 180–181 EBM K6
- [18] El-Dairi M, Bhatti MT, Vaphiades MS. A shot of adrenaline. *Surv Ophthalmol* 2009; 54: 618–624 EBM K6
- [19] Enaida H, Ishibashi T. Brilliant blue in vitreoretinal surgery. *Dev Ophthalmol* 2008; 42: 115–125
- [20] Fine HF, Iranmanesh R, Del Priore LV et al. Surgical outcomes after massive subretinal hemorrhage secondary to age related macular degeneration. *Retina* 2010; 30: 1588–1594 EBM K5
- [21] Fraunfelder FW, Fraunfelder FT. Central serous chorioretinopathy associated with sildenafil. *Retina* 2008; 28: 606–609 EBM K6
- [22] Galloway G, Ramsay A, Jordan K et al. Macular infarction after intravitreal amikacin: mounting evidence against amikacin. *Br J Ophthalmol* 2002; 86: 359–360 EBM K6
- [23] Gandorfer A, Haritoglou C, Kampik A. Toxicity of indocyanine green in vitreoretinal surgery. *Dev Ophthalmol* 2008; 42:

69–81. EBM K5

- [24] Gianni L, Panzini I, Li S et al. International Breast Cancer Study Group. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. *Cancer* 2006; 106: 505–513 EBM K4
- [25] Hausteil KO, Oltmanns G, Rietbock N et al. Differences in color vision impairment caused by digoxin, digitoxin or pentoxifyllin. *J Cardiovasc Pharmacol* 1982; 4: 536–541 EBM K5
- [26] Hayashi K, Ohno-Matsui K, Teramukai S et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularisation after intravitreal bevacizumab or after photodynamic therapy. *Am J Ophthalmol* 2009; 148: 396–408 EBM K3
- [27] Heilweil G, Komarowska I, Zemel E et al. Normal physiological and pathophysiological effects of trypan blue on the retinas of albino rabbits. *Invest Ophthalmol Vis Sci* 2010; 51: 4187–4194
- [28] Kaiser-Kupfer MI, Lippmann ME. Tamoxifen retinopathy. *Cancer Treat Rep* 1978; 62: 315–320 EBM K6
- [29] Kellner U, Kraus H, Foerster MF. Multifocal ERG in chloroquine retinopathy: regional variance of retinal dysfunction. *Graefes Arch Clin Exp Ophthalmol* 2000; 238: 94–97 EBM K6
- [30] Kellner S, Weinitz S, Kellner U. Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy similar to multifocal electroretinography, fundus autofluorescence and near-infrared autofluorescence. *Br J Ophthalmol* 2009; 93: 1444–1447 EBM K5
- [31] Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. *Invest Ophthalmol Vis Sci* 2006; 47: 3531–3538 EBM K5
- [32] Kuhli-Hattenbach C, Fischer IB, Schalnus R et al. Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy. *Am J Ophthalmol* 2010; 149: 316–321 EBM K5
- [33] Lai TY, Chan WM, Li H et al. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. *Am J Ophthalmol* 2005; 140: 794–807 EBM K5
- [34] Laties A, Zrenner E. Viagra (sildenafil citrate) and ophthalmology. *Prog Retin Eye Res* 2002; 21: 485–506
- [35] Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. *Drug Saf* 2009; 32: 1–18
- [36] Lee MS, Fern AI. Fluphenazine and its toxic maculopathy. *Ophthalmic Res* 2004; 36: 237–239 EBM K6
- [37] Lommatzsch A, Heimes B, Gutfleisch M et al. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. *Eye (Lond)* 2009; 23: 2163–2168 EBM K4
- [38] Longmuir R, Lee AG, Rouleau J. Cotton wool spots associated with interferon beta-1 alpha therapy. *Semin Ophthalmol* 2007; 22: 49–53 EBM K6
- [39] Macher JP, Lévy S. Effect of ivabradine, a novel antianginal agent, on driving performance: A randomized, double-blind, placebo-controlled trial in healthy volunteers. *Clin Drug Investig* 2009; 29: 339–348 EBM K1
- [40] Mauguet-Faÿsse M, Gambrelle J, Quaranta-EI Maftouhi M. Optical coherence tomography in tamoxifen retinopathy. *Breast Cancer Res Treat* 2006; 99: 117–118 EBM K6
- [41] Marmor MF, Kellner U, Lai TYY et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. *Ophthalmology* 2011 [im Druck]
- [42] Murata M, Tamura Y, Ohsawa M et al. Central retinal vein occlusion in hypertensive patients with chronic hepatitis C treated with interferon alpha and ribavirin. *Jpn J Ophthalmol* 2008; 52: 511–513 EBM K6
- [43] Okuse C, Yotsuyanagi H, Nagase Y et al. Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C. *World J Gastroenterol* 2006; 12: 3756–3759 EBM K5
- [44] Payne JF, Bergstrom C, Yan J et al. Residual triamcinolone acetonide sequestered in the fovea after macular hole repair. *Retina* 2010 [Epub ahead of print] EBM K6
- [45] Rodriguez-Padilla JA, Hedges TR 3rd, Monson B et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. *Arch Ophthalmol* 2007; 125: 775–780 EBM K6
- [46] Rosenbaum JD, Krumholz DM, Metz DM. Gentamicin retinal toxicity after cataract surgery in an eye that underwent vitrectomy. *Ophthalmic Surg Lasers* 1997; 28: 236–238 EBM K6
- [47] Rosenthal AR, Kolb H, Bergsma D et al. Chloroquine retinopathy in the rhesus monkey. *Invest Ophthalmol Vis Sci* 1978; 17: 1158–1175 EBM K6

-
- [48] Ruther K, Foerster J, Berndt S et al. Variabilität der retinotoxischen Gesamtdosis Chloroquin/Hydroxychloroquin. *Ophthalmologie* 2007; 104: 875–879 EBM K6
- [49] Schulman JA, Liang C, Kooragayala LM et al. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. *Ophthalmology* 2003; 110: 437–442 EBM K5
- [50] Sieving PA, Chaudhry P, Kondo M et al. Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy. *Proc Natl Acad Sci U S A* 2001; 98: 1835–1840
- [51] Vessey MP, Hannaford P, Mant J et al. Oral contraception and eye disease: findings in two large cohort studies. *Br J Ophthalmol* 1998; 82: 538–542 EBM K4
- [52] Viola F, Barteselli G, Villani E et al. Multimodal imaging including SD-OCT and confocal scanning laser ophthalmoscopy for characterisation of outer retinal pathology in deferoxamine maculopathy. *ARBO Abstract Nr. 337*; 2010 EBM K5
- [53] Wachtlin J, Behme T, Heimann H et al. Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. *Graefes Arch Clin Exp Ophthalmol* 2003; 241: 518–521 EBM K6
- [54] Weleber RG, Denman ST, Hanifin JM et al. Abnormal retinal function associated with isotretinoin therapy for acne. *Arch Ophthalmol* 1986; 104: 831–837 EBM K6
- [55] Wetterholm DH, Winter FC. Histopathology of chloroquine retinal toxicity. *Arch Ophthalmol* 1964; 71: 82–87 EBM K6
- [56] Willmore LJ, Abelson MB, Ben-Menachem E et al. Vigabatrin: 2008 update. *Epilepsia* 2009; 50: 163–73
- [57] Wu HM, Lee AG, Lehane DE et al. Ocular and orbital complications of intraarterial cisplatin. A case report. *J Neuroophthalmol* 1997; 17: 195–198 EBM K6
- [58] Yuen D, Gonder J, Proulx A et al. Comparison of the in vitro safety of intraocular dyes using two retinal cell lines: a focus on brilliant blue G and indocyanine green. *Am J Ophthalmol* 2009; 147: 251–259

Kap. 11

- [1] Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. *Transpl Int* 2000; 13: 313–326 EBM K6
- [2] Behbehani RS, Affel EL, Sergott RC et al. Multifocal ERG in ethambutol associated visual loss. *Br J Ophthalmol* 2005; 89: 976–982 EBM K6
- [3] Carter JE. Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence? *J Neurol Sci* 2007; 262: 89–97 EBM K6
- [4] Chai SJ, Foroozan R. Decreased retinal nerve fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy. *Br J Ophthalmol* 2007; 91: 895–897 EBM K5
- [5] Chan JW, Castellanos A. Infliximab and anterior optic neuropathy: case report and review of the literature. *Graefes Arch Clin Exp Ophthalmol* 2010; 248: 283–287 EBM K6
- [6] Chang V, McCurdy D, Gordon LK. Etanercept associated optic neuropathy. *Clin Experiment Ophthalmol* 2007; 35: 680–682 EBM K6
- [7] Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. *Horm Res* 2007; 68 (Suppl. 5): 41–47 EBM K5
- [8] David-Gütting I, Brenneke HJ, Strohmaier A et al. Leukoencephalopathy under cisplatin therapy. *Rofo* 1995; 163: 460–461 EBM K6
- [9] Ertekin V, Selimoglu MA, Tan H. Pseudotumor cerebri due to hypervitaminosis A or hypervitaminosis D or both in Alagille syndrome. *Headache* 2010; 50: 152–153 EBM K6
- [10] Fraunfelder FW, Fraunfelder FT. Interferon alfa-associated anterior ischemic optic neuropathy. *Ophthalmology* 2010 [Epub ahead of print] EBM K6
- [11] Garg RK. Posterior leukoencephalopathy syndrome. *Postgrad Med J* 2001; 77: 24–28 EBM K6
- [12] Godel V, Nemet P, Lazar M. Chloramphenicol optic neuropathy. *Arch Ophthalmol* 1980; 98: 1417–1421 EBM K6
- [13] Glacet-Bernard A, Kuhn D, Soubrane G. Ocular complications of hormonal treatments: oral contraception and menopausal hormonal replacement therapy. *Contracept Fertil Sex* 1999; 27: 285–290 EBM K6
- [14] Guillet V, Chevrollier A, Cassereau J et al. Ethambutol-induced optic neuropathy linked to OPA1 mutation and mitochondrial toxicity. *Mitochondrion* 2010; 10: 115–124 EBM K4

-
- [15] von Jagow B, Kohnen T. Anterior optic neuropathy associated with adalimumab. *Ophthalmologica* 2008; 222: 292–294
- [16] Johnson LN, Krohel GB, Thomas ER. The clinical spectrum of amiodarone-associated optic neuropathy. *J Natl Med Assoc* 2004; 96: 1477–1491
- [17] Kellner U, Sassmannshausen J. Ethambutol Nebenwirkungen am Auge. *Med Klin (Munich)* 1988; 83: 376–378 EBM K6
- [18] Khawly JA, Rubin P, Petros W et al. Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. *Ophthalmology* 1996; 103: 87–95 EBM K6
- [19] Kocabay G, Erelel M, Tutkun IT et al. Optic neuritis and bitemporal hemianopsia associated with isoniazid treatment in end-stage renal failure. *Int J Tuberc Lung Dis* 2006; 10: 1418–1419 EBM K6
- [20] Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. *Drug Saf* 2009; 32: 1–18 EBM K6
- [21] Liu Y, Dinkin MJ, Loewenstein JI et al. Multifocal electroretinographic abnormalities in ethambutol-induced visual loss. *J Neuroophthalmol* 2008; 28: 278–282 EBM K6
- [22] Masvidal D, Parrish RK 2nd, Lam BL. Structural-Functional Dissociation in Presumed Ethambutol Optic Neuropathy. *J Neuroophthalmol* 2010; 30: 305–310 EBM K6
- [23] McGrath NM, Kent-Smith B, Sharp DM. Reversible optic neuropathy due to metronidazole. *Clin Experiment Ophthalmol* 2007; 35: 585–586 EBM K6
- [24] Menon V, Jain D, Saxena R et al. Prospective evaluation of visual function for early detection of ethambutol toxicity. *Br J Ophthalmol* 2009; 93: 1251–1254 EBM K4
- [25] Mindel JS, Anderson J, Hellkamp A et al. Absence of bilateral vision loss from amiodarone: a randomized trial. *Am Heart J* 2007; 153: 837–842 EBM K2
- [26] Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. *Pharmacotherapy* 2007; 27: 1189–1197 EBM K6
- [27] Nawashiro H. Idiopathic intracranial hypertension associated with sulphasalazine treatment. *Headache* 2008; 48: 1383–1384 EBM K6
- [28] Orakzai A, Guerin M, Beatty S. Disulfiram-induced transient optic and peripheral neuropathy: a case report. *Ir J Med Sci* 2007; 176: 319–321
- [29] Pradhan M, Sharp D, Best S et al. Drug-induced optic neuropathy-TB or not TB. *Surv Ophthalmol* 2010; 55: 378–385 EBM K6
- [30] Purvin V, Kawasaki A, Borruat FX. Optic neuropathy in patients using amiodarone. *Arch Ophthalmol* 2006; 124: 696–701 EBM K5
- [31] Seo JH, Hwang JM, Park SS. Antituberculosis medication as a possible epigenetic factor of Leber's hereditary optic neuropathy. *Clin Experiment Ophthalmol* 2010; 38: 363–366 EBM K5
- [32] Simsek I, Erdem H, Pay S et al. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. *Ann Rheum Dis* 2007; 66: 1255–1258 EBM K6
- [33] Stoffelns BM. Interferon löst okuläre Ischämien aus. Fallserie und Literaturüberblick. *Klin Monbl Augenheilkd* 2006; 223: 367–371 EBM K6
- [34] Tabibian JH, Gutierrez MA. Doxycycline-induced pseudotumor cerebri. *South Med J* 2009; 102: 310–311 EBM K6
- [35] Thomas RJ. Neurotoxicity of antibacterial therapy. *South Med J* 1994; 87: 869–874 EBM K6
- [36] Visani G, Manfroi S, Tosi P et al. All-trans-retinoic acid and pseudotumor cerebri. *Leuk Lymphoma* 1996; 23: 437–442 EBM K6
- [37] Wang MY, Arnold AC, Vinters HV et al. Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. *Am J Ophthalmol* 2000; 130: 367–368 EBM K6

Kap. 12

- [1] Abe K. Psychiatric symptoms associated with oculogyric crisis: A review of literature for the characterization of antipsychotic-induced episodes. *World J Biol Psychiatry* 2006; 7: 70–74
- [2] Absher J, Bale JJ. Aggravation of myasthenia gravis by erythromycin. *J Pediatr* 1991; 119: 155–156
- [3] AlAzwary N, Muayqil T, Siddiqi Z et al. Oculogyric crisis masquerading as ventriculoperitoneal shunt dysfunction. *J Neurosurg* 2008; 109: 944–945

-
- [4] Albert D, Wong V, Henderson E. Ocular complications of vincristine therapy. *Arch Ophthalmol* 1967; 78: 709–713
- [5] Alevizos B, Gatzonis S, Anagnostara C. Myasthenia gravis disclosed by lithium carbonate. *J Neuropsychiatry Clin Neurosci* 2006; 18: 427–429
- [6] Anderson J, Brodsky M. Anticholinergic esotropia. *J Neuroophthalmol* 2008; 28: 359–360
- [7] Antoszyk A, Buckley E. Contralateral decreased visual acuity and extraocular muscle palsies following retrobulbar anesthesia. *Ophthalmol* 1986; 93: 462–465
- [8] Argov Z, Brenner T, Abramsky O. Ampicillin may aggravate clinical and experimental myasthenia gravis. *Arch Neurol* 1986; 43: 255–256
- [9] Bay A, Yilmaz C, Yilmaz N, Oner A. Vincristine induced cranial polyneuropathy. *Indian J Pediatr* 2006; 73: 531–533
- [10] Beal M. Amitriptyline ophthalmoplegia. *Neurology* 1982; 32: 1409
- [11] Bellocchi F, Ansalone G, Scabbia E et al. Mexiletine in treatment of chronic ventricular refractory arrhythmias. *G Ital Cardiol* 1981; 11: 488–497
- [12] Bigby M, Stern R. Adverse reactions to isotretinoin. A report from the Adverse Drug Reaction Reporting System. *J Am Acad Dermatol* 1988; 18: 543–552
- [13] Blanco-Marchite C, Buznego-Suárez L, Fagúndez-Vargas M et al. Miller Fisher syndrome, internal and external ophthalmoplegia after flu vaccination. *Arch Soc Esp Oftalmol* 2008; 83: 433–435
- [14] Boneva N, Brenner T, Argov Z. Gabapentin may be hazardous in myasthenia gravis. *Muscle Nerve* 2000; 23: 1204–1208
- [15] Bonnet M, Angibaud G, Cantagrel A et al. Myasthenia induced by tiopronin in the treatment of rheumatoid arthritis. *Rev Neurol (Paris)* 1995; 151: 67–68
- [16] Brandt T. Positional and positioning vertigo and nystagmus. *J Neurol Sci* 1990; 95: 3–28
- [17] Brüggemann W, Herath H, Ferbert A. Follow-up and immunologic findings in drug-induced myasthenia. *Med Klin (Munich)* 1996; 91: 268–271
- [18] Brumlik J, Jacobs R. Myasthenia gravis associated with diphenylhydantoin therapy for epilepsy. *Can J Neurol Sci* 1974; 1: 127–129
- [19] Burstein A, Fullerton T. Oculogyric crisis possibly related to pentazocine. *Ann Pharmacother* 1993; 27: 874–876
- [20] Bygrave H, Geh J, Jani Y et al. Neurological complications of 5-fluorouracil chemotherapy: case report and review of the literature. *Clin Oncol (R Coll Radiol)* 1998; 10: 334–336
- [21] Çaksen H, Acar N, Odabas, D et al. Isolated left oculomotor nerve palsy following measles. *J Child Neurol* 2002; 17: 784–785
- [22] Chakraborty R, Chatterjee A, Chaudhury S. Olanzapine-induced oculogyric crisis in a patient with schizophrenia. *Indian J Med Sci* 2008; 62: 238–239
- [23] Chan C, Sogg R, Steinman L. Isolated oculomotor palsy after measles immunization. *Am J Ophthalmol* 1980; 89: 446
- [24] Chiaretti A, Schembri Wismayer D, Tortorolo L et al. Salicylate intoxication using a skin ointment. *Acta Paediatr* 1997; 86: 330–331
- [25] Chinchurreta-Capote A, Beltrán-Ureña F, Fernández-Ramos M et al. Contralateral amaurosis and extraocular muscle palsies after retrobulbar injection. *Arch Soc Esp Oftalmol* 2006; 81: 45–47
- [26] Chroni E, Monastirli A, Tsambaos D. Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians. *Drug Saf* 2010; 33: 25–34
- [27] Chrousos G, Cowdry R, Schuelein M, et al. Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine. *Am J Ophthalmol* 1987; 103: 221–224
- [28] Confavreux C, Charles N, Aimard G. Fulminant myasthenia gravis soon after initiation of acebutolol therapy. *Eur Neurol* 1990; 30: 279–281
- [29] Cook F, Davis R, Russo LJ. Internuclear ophthalmoplegia caused by phenothiazine intoxication. *Arch Neurol* 1981; 38: 465–466
- [30] Corbett JJ, Jacobson DM, Thompson HS et al. Downbeating nystagmus and other ocular motor defects caused by lithium toxicity. *Neurology* 1989; 39: 481–487
- [31] Craig S. Phenytoin poisoning. *Neurocrit Care* 2005; 3: 161–170
- [32] Cunningham G. Drug-induced internuclear ophthalmoplegia. *Can Med Assoc J* 1983; 128: 892–893
-

-
- [33] De Bleecker J, De Reuck J, Quatacker J et al. Persisting chloroquine-induced myasthenia? *Acta Clin Belg* 1991; 46: 401–406
- [34] Deuschländer A, Stephan T, Riedel E et al. Nicotine-induced nystagmus correlates with midpontine activation. *Neuroimage* 2008; 41: 479–482
- [35] Dintelmann T SJ, Grehn F. Botulinum toxin injection-treatment of upper lid retraction in thyroid eye disease. *Ophthalmologie* 2005; 102: 247–250
- [36] Du Pasquier R, Vingerhoets F, Safran A et al. Periodic downbeat nystagmus. *Neurology* 1998; 51: 1478–1480
- [37] Eadie MJ, Ferriert M. Chloroquine myopathy. *J Neurol Neurosurg Psychiatr* 1966; 29: 331–337
- [38] Esser J, Brandt T. Pharmacologically-caused eye movement disorders – differential diagnosis and mechanisms of action. *Fortschr Neurol Psychiatr* 1983; 51: 41–56
- [39] Felgenhauer N, Zilker T. Intoxikation mit Amphetaminen und Designer-Drogen. *Internist* 1999; 40: 617–623
- [40] Fenichel GM. Neurological Complications of immunization. *Ann Neurol* 1982; 12: 119–128
- [41] Finsterer J, Artner C, Kladosek A et al. Cavernous sinus syndrome due to vaccination-induced giant cell arteritis. *Arch Intern Med* 2001; 161: 1008–1009
- [42] Fountoulakis K, Siamouli M, Kantartzis S et al. Acute dystonia with low-dosage aripiprazole in Tourette's disorder. *Ann Pharmacother* 2006; 40: 775–777
- [43] Fraunfelder F, Fraunfelder F. Calcium regulating agents. In: Fraunfelder FT, Fraunfelder FW, eds. *Drug-Induced Ocular Side Effects*. 5th ed. Boston: Butterworth-Heinemann; 2001: 482–484
- [44] Fraunfelder FW, Fraunfelder FT. Adverse Ocular Drug Reactions Recently Identified by the National Registry of Drug-Induced Ocular Side Effects. *Ophthalmology* 2004; 111: 1275–1279
- [45] Fraunfelder FW, Richards AB. Diplopia, blepharoptosis, and ophthalmoplegia and 3-Hydroxy-3-Methyl-Glutaryl-CoA reductase inhibitor use. *Ophthalmology* 2008; 115: 2282–2285
- [46] Fraunfelder FW, Fraunfelder FT. Diplopia and Fluoroquinolones. *Ophthalmology* 2009; 116: 1814–1817
- [47] Fredericks C, Giannotta S, Sadun A. Dilantin-induced long-term bilateral total external ophthalmoplegia. *J Clin Neuroophthalmol* 1986; 6: 22–26
- [48] Gatzonis S, Georgaculias N, Singounas E et al. Elimination of oxcarbazepine-induced oculogyric crisis following vagus nerve stimulation. *Neurology* 1999; 52: 1918–1919
- [49] George J, Spokes E. Myasthenic pseudo-internuclear ophthalmoplegia due to penicillamine. *J Neurol Neurosurg Psychiatry* 1984; 47: 1944
- [50] Gordon A, Logan B. Topiramate-positive death-investigation and impaired-driving cases in Washington State. *J Anal Toxicol* 2006; 30: 599–602
- [51] Gorman M, Barkley G. Oculogyric crisis induced by carbamazepine. *Epilepsia* 1995; 36: 1158–1160
- [52] Goszcz H, Groszek B, Urbanik A et al. Suicidal self poisoning with disulfiram in a 15-year old boy with resulting encephalopathy. *Przegl Lek* 1999; 56: 465–468
- [53] Granacher RJ. Neuromuscular problems associated with lithium. *Am J Psychiatry* 1977; 134: 702
- [54] Gupta S, Nolan T, Frank B. Case report of oculogyric crisis with ziprasidone in a minor. *Prim Care Companion J Clin Psychiatry* 2008; 10: 254–255
- [55] Halmagyi G, Lessell I, Curthoys I et al. Lithium-induced downbeat nystagmus. *Am J Ophthalmol* 1989; 107: 664–670
- [56] Booker HE, Chun RW, Sanguino M. Myasthenia gravis syndrome associated with trimethadione. *JAMA* 1970; 212: 2262–2263
- [57] Henderson R, Wijdicks E. Downbeat nystagmus associated with intravenous patient-controlled administration of morphine. *Anesth Analg* 2000; 91: 691–692
- [58] Hogan R, Collins S, Reed R et al. Neuro-ophthalmological signs during rapid intravenous administration of phenytoin. *J Clin Neurosci* 1999; 6: 494–497
- [59] Horiguchi J, Inami Y. Effect of clonazepam on neuroleptic-induced oculogyric crisis. *Acta Psychiatr Scand* 1989; 80: 521–523
- [60] Howard JJ. Adverse drug effects on neuromuscular transmission. *Semin Neurol* 1990; 10: 89–102
- [61] Imamura T, Ejima A, Sahara M et al. Cerebellar atrophy and persistent cerebellar ataxia after acute intoxication of phenytoin. *No To Shinkei* 1992; 44: 149–153
-

-
- [62] Ishiyama G, Ishiyama A, Kerber K et al. Gentamicin ototoxicity: clinical features and the effect on the human vestibulo-ocular reflex. *Acta Otolaryngol* 2006; 126: 1057–1061
- [63] Jehan F, Hagan Jr, Whittaker T et al. Diplopia and ptosis following injection of local anesthesia without hyaluronidase. *J Cataract Refract Surg* 2001; 27: 1876–1879
- [64] Jennett A, Bali D, Jasti P et al. Telithromycin and myasthenic crisis. *Clin Infect Dis* 2006; 43: 1621–1622
- [65] Jhee S, Zarotsky V, Mohaupt S et al. Delayed onset of oculogyric crisis and torticollis with intramuscular haloperidol. *Ann Pharmacother* 2003; 37: 1434–1437
- [66] Kao K, Kwan S, Lin K et al. Coexistence of Parkinson's disease and myasthenia gravis: a case report. *Clin Neurol Neurosurg* 1993; 95: 137–139
- [67] Katz L, Lesser R, Merikangas J et al. Ocular myasthenia gravis after D-penicillamine administration. 1989; 73: 1015–1018
- [68] Keane J. Bilateral ocular paralysis: analysis of 31 inpatients. *Arch Neurol* 2007; 64: 178–180
- [69] Khella S, Kozart D. Unmasking and exacerbation of myasthenia gravis by ophthalmic solutions: betaxolol, tobramycin, and dexamethasone. A case report. *Muscle Nerve* 1997; 20: 631
- [70] Kim W, Lee K, Kim Y et al. Acute oculogyric crisis in a patient taking clobopride. *Intern Med* 2008; 47: 551–552
- [71] Kimbrough R, Mewis L, Stewart R. D-penicillamine and the ocular myasthenic syndrome. *Ann Ophthalmol* 1981; 13: 1171–1172
- [72] Klimek A. The myasthenic syndrome after chloroquine. *Neurol Neurochir Pol* 1999; 33: 951–954
- [73] Langmuir A, Bregman D, Kurland L et al. An epidemiologic and clinical evaluation of Guillain-Barre syndrome reported in association with the administration of swine influenza vaccines. *Am J Epidemiol* 1984; 119: 841–879
- [74] Lee M, Lessell S. Lithium-induced periodic alternating nystagmus. *Neurology* 2003; 60: 344
- [75] Leiderman Y, Lessell S, Cestari D. Recurrent isolated sixth nerve palsy after consecutive annual influenza vaccinations in a child. *J AAPOS* 2009; 13: 317–318
- [76] Lifshitz M, Gavrilov V, Sofer S. Signs and symptoms of carbamazepine overdose in young children. *Pediatr Emerg Care* 2000; 16: 26–27
- [77] Lipton I. Myasthenia gravis unmasked by lithium carbonate. *J Clin Psychopharmacol* 1987; 7: 57
- [78] Lou E, Abou-Zeid N. A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis. *South Med J* 2006; 99: 1290–1291
- [79] Manlapaz J. Abducens nerve palsy in dilantin intoxication. *J Pediatr* 1959; 55: 73–77
- [80] Manoguerra A, Whitney C, Clark R et al. Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. *J Toxicol Clin Toxicol* 1995; 33: 463–465
- [81] Marks J. Motor polyneuropathy and nystagmus associated with chloroquine phosphate. *Postgrad Med J* 1979; 55: 569
- [82] May E, Calvert P. Aggravation of myasthenia gravis by erythromycin. *Ann Neurol* 1990; 28: 577–579
- [83] McLean R, Gottlob I. The pharmacological treatment of nystagmus: a review. *Expert Opin Pharmacother* 2009; 10: 1805–1816
- [84] Meaney T, Musadiq M, Corridan P. Diplopia following intravenous administration of pamidronate. *Eye* 2004; 18: 103–104
- [85] Mendhekar D, Duggal H. Isolated oculogyric crisis on clozapine discontinuation. *J Neuropsychiatry Clin Neurosci* 2006; 18: 424–425
- [86] Mendhekar D, B Y, Aggarwal A. Amisulpride-induced both oculogyric crisis and trismus. *Indian J Med Sci* 2008; 62: 239–241
- [87] Meyer D, Hamilton R, Gimbel H. Myasthenia gravis-like syndrome induced by topical ophthalmic preparations. A case report. *J Clin Neuroophthalmol* 1992; 12: 210–212
- [88] Moore B, Safani M, Keese J. Possible exacerbation of myasthenia gravis by ciprofloxacin. *Lancet* 1988; 1: 882
- [89] Mulvihill A, Cackett P, George N et al. Nystagmus secondary to drug exposure in utero. *Br J Ophthalmol* 2007; 91: 613–615
- [90] Mumford C, Ginsberg L. Ciprofloxacin and myasthenia gravis. *BMJ* 1990; 301: 818
- [91] Neary D, Thurston H, Pohl J. Development of extrapyramidal symptoms in hypertensive patients treated with diazoxide.

-
- Br Med J 1973; 3: 474–475
- [92] Neil J, Himmelhoch J, Licata S. Emergence of myasthenia gravis during treatment with lithium carbonate. *Arch Gen Psychiatry* 1976; 33: 1090–1092
- [93] Oh S, Shin B, Lee Y et al. Benzotropine-induced esotropia and mydriasis. *J Neuroophthalmol* 2007; 27: 312–313
- [94] Oh S, Dhall R, Young A et al. Statins may aggravate myasthenia gravis. *Muscle Nerve* 2008; 38: 1101–1107
- [95] Oliverio P, Restrepo L, Mitchell S et al. Reversible tacrolimus-induced neurotoxicity isolated to the brain stem. *AJNR Am J Neuroradiol* 2000; 21: 1251–1254
- [96] Padoan S KK, Magnusson M, Pyykkö I et al. Reduction of gain and time constant of vestibulo-ocular reflex in man induced by diazepam and thiopental. *J Vestib Res* 1990–1991; 1: 97–104
- [97] Peiris RS, Peckler BF. Cimetidine-induced dystonic reaction. *J Emerg Med* 2001; 21: 27–29
- [98] Peñarrocha-Diago M, Sanchis-Bielsa J. Ophthalmologic complications after intraoral local anesthesia with articaine. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2000; 90: 21–24
- [99] Penn A, Low B, Jaffe I et al. Drug-induced autoimmune myasthenia gravis. *Ann N Y Acad Sci* 1998; 841: 433–449
- [100] Perrot X, Bernard N, Vial C et al. Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. *Neurology* 2006; 67: 2256–2258
- [101] Peterson B. Prevalence of gabapentin in impaired driving cases in Washington State in 2003–2007. *J Anal Toxicol* 2009; 33: 545–549
- [102] Pijpers E, van Rijswijk RE, Takx-Köhlen B et al. A clarithromycin-induced myasthenic syndrome. *Clin Infect Dis* 1996; 22: 175–176
- [103] Pittinger C, Eryasa Y, Adamson R. Antibiotic-induced paralysis. *Anesth Analg* 1970; 49: 487–501
- [104] Porges Y, Blumen S, Fireman Z et al. Cyclosporine-induced optic neuropathy, ophthalmoplegia, and nystagmus in a patient with Crohn disease. *Am J Ophthalmol* 1998; 126: 607–609
- [105] Pradhan S, Pardasani V, Ramteke K. Azithromycin-induced myasthenic crisis: reversibility with calcium gluconate. *Neurol India* 2009; 57: 352–353
- [106] Praharaj SK JA, Sarkar S, Sinha VK. Olanzapine-induced tardive oculogyric crisis. *J Clin Psychopharmacol* 2009; 29: 604–606
- [107] Price J, Farish S, Taylor H et al. Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. *Ophthalmology* 1997; 104: 865–868
- [108] Puri V, Chaudhry N. Total external ophthalmoplegia induced by phenytoin: a case report and review of literature. *Neurol India* 2004; 52: 386–387
- [109] Purvin V, Kawasaki A, Smith K et al. Statin-associated myasthenia gravis: report of 4 cases and review of the literature. *Medicine (Baltimore)* 2006; 85: 82–85
- [110] Reeves A, So E, Sharbrough F et al. Movement disorders associated with the use of gabapentin. *Epilepsia* 1996; 37: 988–990
- [111] Remler B, Leigh R, Osorio I et al. The characteristics and mechanisms of visual disturbance associated with anticonvulsant therapy. *Neurology* 1990; 40: 791–796
- [112] Riva R, Contin M, Albani F et al. Lateral gaze nystagmus in carbamazepine-treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its 10,11-epoxide metabolite. *Ther Drug Monit* 1985; 7: 277–282
- [113] Roggenkamper P. Blepharospasmus-Behandlung mit Botulinus-Toxin (Verlaufsbeobachtungen). *Klin Monbl Augenheilkd* 1986; 189: 283–285
- [114] Ronzière T, Auzou P, Ozsancak C et al. Myasthenic syndrome induced by lithium. *Presse Med* 2000; 29: 1043–1044
- [115] Rosenhagen M, Schmidt U, Winkelmann J et al. Olanzapine-induced oculogyric crisis. *J Clin Psychopharmacol* 2006; 26: 431
- [116] Ross J. Visual disturbances due to the use of digitalis and similar preparations. *Am J Ophthalmol* 1950; 33: 1438–1439
- [117] Rottach K, Wohlgemuth W, Dzaja A et al. Effects of intravenous opioids on eye movements in humans: possible mechanisms. *J Neurol* 2002; 249: 1200–1205
- [118] Rubin M, Thomas W. Diplopia and loss of accommodation due to chloroquine. *Arthritis Rheum* 1970; 13: 75–82
- [119] Sandler S, Tobin W, Henderson E. Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. *Neurology*
-

1969; 19: 367–374

- [120] Sandyk R. Total external ophthalmoplegia induced by phenytoin. A case report. *S Afr Med J* 1984; 65: 141–142
- [121] Sandyk R. Oculogyric crisis induced by lithium carbonate. *Eur Neurol* 1984; 23: 92–94
- [122] Saul R, Selhorst J. Downbeat nystagmus with magnesium depletion. *Arch Neurol* 1981; 38: 650–652
- [123] Scheinfeld N. The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face. *Dermatol Online J* 2005; 11: 9
- [124] Scheschonka A, Beuche W. Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. *Pain* 2003; 104: 423–424
- [125] Schneider E, Jungbluth H, Oppermann F. Die akute Isoniazid-Intoxikation – Eine neurologische, elektroencephalographische und toxikologische Verlaufsuntersuchung. *Klin Wochenschr* 1971; 49: 904–910
- [126] Schneider S, Udani V, Sankhla C et al. Recurrent acute dystonic reaction and oculogyric crisis despite withdrawal of dopamine receptor blocking drugs. *Mov Disord* 2009; 24: 1226–1229
- [127] Schumm F, Wiethölter H, Fateh-Moghadam A. Myasthenie-Syndrom unter Chloroquin-Therapie. *Dtsch Med Wochenschr* 1981; 106: 51–52
- [128] Schumock G, Martinez E. Acute oculogyric crisis after administration of prochlorperazine. *South Med J* 1991; 84: 407–408
- [129] Selimoglu E. Aminoglycoside-induced ototoxicity. *Curr Pharm Des* 2007; 13: 119–126
- [130] Seymour J. Carbamazepine overdose. Features of 33 cases. *Drug Saf* 1993; 8: 81–88
- [131] Sieb J. Fluoroquinolone antibiotics block neuromuscular transmission. *Neurology* 1998; 50: 804–807
- [132] Skorin LJ, Onofrey B, DeWitt J. Phenothiazine-induced oculogyric crisis. *J Am Optom Assoc* 1987; 58: 316–318
- [133] Snavely S, Hodges G. The neurotoxicity of antibacterial agents. *Ann Intern Med* 1984; 101: 92–104
- [134] Somjen G, Hilmy M, Stephen C. Failure to anesthetize human subjects by intravenous administration of magnesium sulfate. *J Pharmacol Exp Ther* 1966; 154: 652–659
- [135] Spector R, Davidoff R, Schwartzman R. Phenytoin-induced ophthalmoplegia. *Neurology* 1976; 26: 1031–1034
- [136] Spector R, Schnapper R. Amitriptyline-induced ophthalmoplegia. *Neurology* 1981; 31: 1188–1190
- [137] von Stuckrad-Barre S, Wekerle G, Pfefferkorn T et al. External ophthalmoplegia caused by amitriptyline poisoning. *Nervenarzt* 2002; 73: 174–176
- [138] Sucker C, Lambers C, Stockscläder M et al. Neurotoxizität von 5-Fluorouracil. *Dtsch Med Wochenschr* 2002; 127: 2011–2014
- [139] Teta D, Uldry P, Regli F. Reversible ophthalmoplegia, cerebellar syndrome and vigilance disorders following phenytoin poisoning. *Schweiz Med Wochenschr* 1990; 120: 1504–1507
- [140] Than Trong T, Gatinel D, Uteza Y et al. Nystagmus retractorius d'origine vasculaire. *J Fr Ophtalmol* 1998; 21: 440–442
- [141] Tipples K, Kolluri R, Raouf S. Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion. *J Oncol Pharm Pract* 2009; 15: 237–239
- [142] Toker E, Yenice O, Oğüt M. Isolated abducens nerve palsy induced by vincristine therapy. *J AAPOS* 2004; 8: 69–71
- [143] Tracis S, Rosati G, Monaco M et al. Successful treatment of acquired pendular elliptical nystagmus in multiple sclerosis with isoniazid and base-out prisms. *Neurology* 1990; 40: 492–494
- [144] Tutuncu R GH. Oculogyric crisis with sertindole monotherapy. *Pharmacopsychiatry* 2010; 43: 119–120
- [145] Ueno S, Takahashi M, Kajiyama K et al. Parkinson's disease and myasthenia gravis: adverse effect of trihexyphenidyl on neuromuscular transmission. *Neurology* 1987; 37: 832–833
- [146] Ueyama H, Nishimura M, Tashiro C. Naloxone reversal of nystagmus associated with intrathecal morphine administration. *Anesthesiology* 1992; 76: 153
- [147] Uzun O, Doruk A. Tardive oculogyric crisis during treatment with clozapine: report of three cases. *Clin Drug Investig* 2007; 27: 861–864
- [148] Vannaprasaht S, Tawalee A, Mayurasakorn N et al. Ceftazidime overdose-related nonconvulsive status epilepticus after intraperitoneal instillation. *Clin Toxicol (Phila)* 2006; 44: 383–386
- [149] Viana BM, Prais H, Camargos S et al. Ziprasidone-related oculogyric crisis in an adult. *Clin Neurol Neurosurg* 2009; 111: 883–885

-
- [150] Wang C, Tian J, Liang P, Sun F. Diazepam-induced changes of optokinetic nystagmus fast phase. *Exp Brain Res* 2005; 167: 446–450
- [151] Wildemann B, Jarius S, Hartmann M et al. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. *Neurology* 2009; 72: 2132–2133
- [152] Wilhelm W, Biedler A, Hammadeh M et al. Remifentanyl for oocyte retrieval: A new single-agent monitored anaesthesia care technique. *Anaesthesist* 1999; 48: 698–704
- [153] Williams DP, Troost BT, Rogers J. Lithium-induced downbeat nystagmus. *Arch Neurol* 1988; 45: 1022–1023
- [154] Wittbrodt ET. Drugs and myasthenia gravis. An update. *Arch Intern Med* 1997; 157: 399–408
- [155] Wutthiphon S, Kowal L, O'Day J et al. Diplopia following subcutaneous injections of botulinum A toxin for facial spasms. *J Pediatr Ophthalmol Strabismus* 1997; 34: 229–234
- [156] Yoshida I, Sakaguchi Y, Matsuishi T et al. Acute accidental overdose of haloperidol in children. *Acta Paediatr* 1993; 82: 877–880
- [157] Yousuf S, Khan A. Presenting features suggestive for later recurrence of idiopathic sixth nerve paresis in children. *J AAPOS* 2007; 11: 452–455

Kap. 13

- [1] Abel AD, Carlson JA, Bakri S et al. Sclerosing lipogranuloma of the orbit after periorcular steroid injection. *Ophthalmology* 2003; 110: 1841–1845
- [2] Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. *Ophthalmology* 1999; 106: 1947–1950 EBM K1
- [3] Berg G, Andersson T, Sjödel L et al. Development of severe thyroid-associated ophthalmopathy in a patient with disseminated thyroid cancer treated with recombinant human thyrotropin/radioiodine and retinoic acid. *Thyroid* 2005; 15: 1389–1394 EBM K6
- [4] Bernardino CR, Mihora LD, Fay AM et al. Orbital complications of hydrogel scleral buckles. *Ophthal Plast Reconstr Surg* 2006; 22: 206–208 EBM K6
- [5] Borchard K, Puy R, Nixon R. Hyaluronidase allergy: a rare cause of periorbital inflammation. *Australas J Dermatol* 2010; 51: 49–51 EBM K6
- [6] Castro E, Seeley M, Kosmorsky G et al. Orbital compartment syndrome caused by intraorbital bacitracin ointment after endoscopic sinus surgery. *Am J Ophthalmol* 2000; 130: 376–378 EBM K6
- [7] Chen Y, Du XY. Functional properties and intracellular signaling of CCN1 / Cyr61. *J Cell Biochem* 2007; 6: 1337–1345
- [8] Dal Canto AJ, Downs-Kelly E, Perry JD. Ptosis and orbital fat prolapse after posterior sub-tenon's capsule triamcinolone injection. *Ophthalmology* 2005; 112: 1092–1095 EBM K6
- [9] Delaere L, Zeyen T, Foets B et al. Allergic reaction to hyaluronidase after retrobulbar anaesthesia: a case series and review. *Int Ophthalmol* 2008; 29: 521–528 EBM K6
- [10] D'Hermies F, Korobelnik JF, Caputo G et al. Encapsulation of scleral buckling materials: a study of sixty specimens. *Ophthalmology* 1998; 105: 1079–1086 EBM K6
- [11] Diatchuk V, Rehany U, Rumelt S. Spontaneous subperiosteal orbital hemorrhage following thrombolytic therapy for myocardial infarction. *Ophthal Plast Reconstr Surg* 2007; 23: 482–484 EBM K6
- [12] Droste PJ, Ellis FD, Sondhi N et al. Linear subcutaneous fat atrophy after corticosteroid injection of perocular hemangiomas. *Am J Ophthalmol* 1988; 105: 65–69 EBM K6
- [13] Dry J, Aron-Rosa A, Pradalier A. Onset of exophthalmos during treatment with lithium carbonate. *Biological hyperthyroidism. Therapie* 1974; 29: 701–708 EBM K6
- [14] Esmaeli B, Prieto VG, Butler CE et al. Severe periorbital edema secondary to STI571 (Gleevec). *Cancer* 2002; 95: 881–887 EBM K6
- [15] Figueira EC, Francis IC, Wilcsek GA. Scleral MIRAgel causing bony erosion. *Orbit* 2007; 26: 65–69 EBM K6
- [16] Fillippopoulos T, Paula JS, Torun N et al. Periorbital changes associated with topical bimatoprost. *Ophthal Plast Reconstr Surg* 2008; 24: 302–307 EBM K6
- [17] Fledelius HC. Exophthalmometry and thyroid disease. The value of the Hertel measurement evaluated by a group of patients with thyroid diseases and a control group. *Ugeskr Laeger* 1994; 44: 6528–6531 EBM K4
- [18] Fraunfelder FW, Solomon J, Druker BJ et al. Ocular side effects associated with imatinib mesylate (Gleevec). *J Ocul*

-
- Pharmacol Ther 2003; 19: 371–375
- [19] Goldberg RA, Weisman JS, McFarland JE et al. Orbital inflammation and optic neuropathies associated with chronic sinusitis of intranasal cocaine abuse. *Arch Ophthalmol* 1989; 107: 831–835 EBM K6
- [20] Gupta OP, Boynton JR, Sabini P et al. Proptosis after retrobulbar corticosteroid injections. *Ophthalmology* 2003; 110: 443–447 EBM K6
- [21] Heuchel R, Berg A, Tallquist M et al. Platelet derived growth factor B receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling. *Proc Natl Acad Sci USA* 1999; 96: 11410–11415
- [22] Katz B, Carmody R. Exophthalmos induced by exogenous steroids. *J Clin Neuroophthalmol* 1986; 6: 250–253 EBM K6
- [23] Kearney JJ, Lahey JM, Borirakchanyavat S et al. Complications of hydrogel explants used in scleral buckling surgery. *Am J Ophthalmol* 2004; 137: 96–100 EBM K6
- [24] Kelly W. Exophthalmos in Cushing's syndrome. *Clin Endocrinol* 1996; 45: 167–170
- [25] Kempeneers R, Dralands L, Ceuppens J. Hyaluronidase induced orbital pseudotumor as a complication of retrobulbar anaesthesia. *Bull Soc Belge Ophthalmol* 1992; 243: 159–166 EBM K6
- [26] Kirby B, Butt A, Morrison AM et al. Type I allergic reaction to hyaluronidase during ophthalmic surgery. *Contact Dermatitis* 2001; 44: 52 EBM K6
- [27] Kumar S, Schiefer R, Coenen MJ et al. A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts. *Thyroid* 2010; 20: 59–65
- [28] Lauer AK, Wobig JL, Shults WT et al. Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy. *Am J Ophthalmol* 1999; 127: 230–233 EBM K6
- [29] Leibovitch I, Tamblin D, Casson R et al. Allergic reaction to hyaluronidase: a rare cause of orbital inflammation after cataract surgery. *Graefes Arch Clin Exp Ophthalmol* 2006; 244: 944–949 EBM K6
- [30] Liang Y, Li C, Guzman VM et al. Comparison of prostaglandin F2alpha, bimatoprost (prostamid), and butaprost (EF2 agonist) on Cyr61 and connective tissue growth factor gene expression. *J Biol Chem* 2003; 29: 27267–27277
- [31] Lippert H. *Lehrbuch Anatomie*. 3. Aufl. München: Urban und Schwarzenberg; 1993
- [32] Maurice DM. Drug delivery to the posterior segment from drops. *Surv Ophthalmol* 2002; 47: S 41–52
- [33] Mbekeani JN, Slamovits TL. Bisphosphonate-induced orbital inflammation. *J Neuroophthalmol* 2010; 30: 205–206 EBM K6
- [34] McCulley TJ, Kersten RC. Periocular inflammation after retrobulbar chlorpromazine (thorazine) injection. *Ophthal Plast Reconstr Surg* 2006; 22: 283–285 EBM K6
- [35] McDermott MT, Burman KD, Hofeldt FD et al. Lithium-associated thyrotoxicosis. *Am J Med* 1986; 80: 1245–1248 EBM K6
- [36] Merkur AB, Jardaleza MS, Iliff NT et al. Periocular petrolatum. *Ophthal Plast Reconstr Surg* 2005; 21: 23–31 EBM K6
- [37] Mulvihill A, Budning A, Jay V et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. *Arch Ophthalmol* 2003; 121: 1120–1124 EBM K6
- [38] Murray TG, Ciciarelli N, O'Brien JM et al. Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. *Arch Ophthalmol* 1997; 115: 1286–1290
- [39] Namba H, Yamashita S, Morita S et al. Retinoic acid inhibits human thyroid peroxidase and thyroglobulin gene expression in cultured human thyrocytes. *J Endocrinol Invest* 1993; 16: 87–93
- [40] Panzer SW, Patrinely JR, Wilson HK. Exophthalmos and iatrogenic Cushing's syndrome. *Ophthal Plast Reconstr Surg* 1994; 10: 278–82. EBM K6
- [41] Pasquali D, Bellastella A, Colantuoni V et al. All-trans retinoic acid- and N-(4-hydroxyphenyl)-retinamide-induces growth arrest and apoptosis in orbital fibroblasts in Graves' disease. *Metabolism* 2003; 52: 1387–1392
- [42] Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. *Optom Vis Sci* 2004; 8: 574–577 EBM K6
- [43] Riemann CD, Foster JA, Kosmorsky GS. Direct orbital manometry in healthy patients. *Ophthal Plast Reconstr Surg* 1999; 15: 121–125 EBM K4
- [44] Scholl HPN, Thiel HJ, Schlote T. Orbitablutung als Folge einer heparininduzierten Thrombozytopenie. *Klin Monbl Augenheilkd* 1999; 215: 197–200 EBM K6
- [45] Slansky HH, Kolbert G, Gartner S. Exophthalmos induced by steroids. *Arch Ophthalmol* 1967; 77: 579–581 EBM K6

-
- [46] Smith JR, George RK, Rosenbaum JT. Lower eyelid herniation of orbital fat may complicate periocular corticosteroid injection. *Am J Ophthalmol* 2002; 133: 845–847 EBM K6
- [47] Stiebel-Kalish H, Robenshtok E, Gatton DD. Pathophysiology of Graves' ophthalmopathy. *Pediatr Endocrinol Rev* 2010; 7 (Suppl. 2): 178–181
- [48] Sugar J. Ocular side effects of systemic therapy of cutaneous diseases. *Int Ophthalmol Clin* 1985; 25: 173–183
- [49] Tappeiner C, Perren B, Iliev ME et al. Orbitale Fettgewebsatrophie bei lokaler Bimatoprost-Therapie – Kann Bimatoprost einen Exophthalmus verursachen? *Klin Monbl Augenheilkd* 2008; 225: 443–445 EBM K6
- [50] Todorovic V, Chen CC, Hay N et al. The matrix protein CCN (CYR61) induces apoptosis in fibroblasts. *J Cell Biol* 2005; 171: 559–68
- [51] van Zeijl CJ, Fliers E, van Koppen CJ et al. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients. *Thyroid* 2010; 20: 535–544
- [52] Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. *N Engl J Med* 1995; 332: 1330–1335 EBM K6
- [53] Woodward DF, Krauss AH, Chen J et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). *J Pharmacol Exp Ther* 2003; 305: 772–785
- [54] Wuttke H, Schlieter D. Stimulation of endogenous TSH secretion and endocrine orbitopathy. *Med Klin* 1980; 75: 658–662 EBM K4
- [55] Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. *Ocul Pharmacol Ther* 2009; 25: 471–472 EBM K6
- [56] Yang EB, Birkholz ES, Lee AG. Another case of bisphosphonate-induced orbital inflammation. *J Neuroophthalmol* 2010; 30: 94–95 EBM K6
- [57] Zuercher D, Tajouri N, von Issum C et al. Spontaneous orbital haemorrhage into the lateral rectus muscle. *Klin Monatsbl Augenheilkd* 2008; 225: 435–437 EBM K6

Kap. 14

- [1] Aston-Jones G, Cohen JD. Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. *J Comp Neurol* 2005; 493: 99–110
- [2] Awan KJ. Mydriasis and conjunctival paresthesia from local gentamicin. *Am J Ophthalmol* 1985; 99: 723–724 EBM K6
- [3] Bard LA. Transient myopia associated with promethazine (phenergan) therapy. Report of a case. *Am J Ophthalmol* 1964; 58: 682–686 EBM K6
- [4] Beasley FJ. Transient myopia and retinal edema during hydrochlorothiazide (Hydrodiuril) therapy. *Arch Ophthalmol* 1961; 65: 212–213 EBM K6
- [5] Beasley FJ. Transient myopia and retinal edema during ethoxzolamide (cardrase) therapy. *Arch Ophthalmol* 1962; 68: 490–491 EBM K6
- [6] Bernstein HN. Chloroquin ocular toxicity. *Surv Ophthalmol* 1967; 124: 15–47
- [7] Bhattacharyya KB, Basu S. Acute myopia induced by topiramate: report of a case and review of the literature. *Neurol India* 2005; 53: 108–109 EBM K6
- [8] Black M. Transient myopia after use of acetazolamide. *Arch Ophthalmol* 1956; 55: 546–547 EBM K6
- [9] Bohnsack BL, Parker JW. Positive apraclonidine test within two weeks of onset of Horner syndrome caused by carotid artery dissection. *J Neuroophthalmol* 2008; 28: 235–236 EBM K6
- [10] Bovino JA, Marcus DF. The mechanism of transient myopia induced by sulfonamide therapy. *Am J Ophthalmol* 1982; 94: 99–102 EBM K6
- [11] Canning CR, Hague S. Ocular quinine toxicity. *Br J Ophthalmol* 1988; 72: 23–26 EBM K6
- [12] Conner CS, Watanabe AS. Clonidine overdose: a review. *Am J Hosp Pharm* 1979; 36: 906–911
- [13] Corridan P, Nightingdale S, Mashoudi N, et al. Acute angle-closure glaucoma following botulinum toxin injection for blepharospasm. *Br J Ophthalmol* 1990; 74: 309–310 EBM K6
- [14] Creighton FJ, Ghodse AH. Naloxone applied on conjunctiva as a test for physical opiate dependence. *Lancet* 1989; 1: 748–750 EBM K4

-
- [15] Dangel ME, Weber PA, Leier CB. Transient myopia following isosorbide dinitrate. *Ann Ophthalmol* 1983; 15: 1156–1158 EBM K6
- [16] Donnenfeld E, Perry HD, Chruscicki DA et al. A comparison of the fourth generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability. *Curr Med Res Opin* 2004; 20: 1753–1758 EBM K3
- [17] Duke-Elder WS. Changes in refraction in diabetes mellitus. *Br J Ophthalmol* 1925; 9: 167–187
- [18] Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. *Br J Ophthalmol* 1988; 95: 1529–1534 EBM K5
- [19] Edwards TS. Transient myopia due to tetracycline. *J Am Med Assoc* 1963; 186: 69–70 EBM K6
- [20] Ericson LA. Hygroton-induced myopia and retinal edema. *Acta Ophthalmol* 1963; 41: 538–543 EBM K6
- [21] Fraunfelder FT. Drug-induced ocular side effects. 4th ed. Baltimore: Williams & Wilkins; 1996: 12–20, 112–115, 246–247, 335
- [22] Ganginato JL, Keltner JL. Abnormalities of the pupil and visual-evoked potential in quinine amblyopia. *Am J Ophthalmol* 1980; 89: 425–430 EBM K6
- [23] Grinbaum A, Ashkenazi I, Blumenthal M. Transient myopia following metronidazole treatment for *Trichomonas vaginalis* (letter). *JAMA* 1992; 267: 511–512 EBM K6
- [24] Grossman EE, Hanley W. Transient myopia during treatment for hypertension with autonomic blocking agents. *Arch Ophthalmol* 1960; 63: 133–135 EBM K6
- [25] Hook SR, Holladay JT, Prager TC et al. Transient myopia induced by sulfonamides. *Am J Ophthalmol* 1986; 101: 495–496 EBM K6
- [26] Imperia PS, Lazarus HM, Lass JH. Ocular complications of systemic cancer therapy. *Surv Ophthalmol* 1989; 34: 209–230
- [27] Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. *Clin Pharmacol Ther* 1972; 13: 923–930
- [28] Jampolsky A, Flom B. Transient myopia associated with anterior displacement of the crystalline lens. *Am J Ophthalmol* 1953; 36: 81–85 EBM K6
- [29] Kerger H, Paul W, Wild H. Über den Myopisierungseffekt von Pilocarpin (1%)-, Jestril (Doryl) (1%)- und Neoeserin (Prostigmin) (3%)-Augentropfen. *Acta Ophthalmol* 1969; 47: 189–201 EBM K4
- [30] Knorrung L, Mornstad H, Forsgren L et al. Acute effects of different antidepressant drugs on salivary secretion and accommodation range. *Pharmacopsychiatry* 1986; 19: 106–110 EBM K1
- [31] Krieg PH, Schipper I. Drug-induced ciliary body oedema: a new theory. *Eye* 1996; 10:121–126
- [32] Larson MD. Mechanism of opioid-induced pupillary effects. *Clin Neurophysiol* 2008; 119: 1358–1364 EBM K4
- [33] Leopold IH, Comroe JH. Effect of intramuscular administration of morphine, atropine, scopolamine and neostigmine on the human eye. *Arch Ophthalmol* 1948; 40: 285–290
- [34] Levine L. Reported ocular side effects of the ten most frequently prescribed drugs. *J Am Optom Ass* 1979; 50: 221–227
- [35] Lin SF, Lin PK, Chang FL et al. Transient hyperopia after intensive treatment of hyperglycemia in newly diagnosed patients. *Ophthalmologica* 2009; 223: 68–71 EBM K5
- [36] Lin SL, Liang SS. Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution. *J Ocul Pharmacol Ther* 1995; 11: 267–278 EBM K4
- [37] Manor RS, Dickerman Z, Laron Z. Myopia during bromocriptine treatment. *Lancet* 1981; 10: 102 EBM K6
- [38] McLane NJ, Carrol DM. Ocular manifestations of drug abuse. *Surv Ophthalmol* 1986; 30: 298–313
- [39] Meythaler H, Ruppert W. Vergleichende Untersuchungen über den myopisierenden und miotischen Effekt von Pilocarpin und Aceclidine (Glaucotat). *Klin Monbl Augenheilkd* 1971; 181: 234–245 EBM K4
- [40] Mitchell AA, Lovejoy FH, Goldman O. Drug interactions associated with miosis in comatose children. *J Pediatr* 1976; 89: 303–305 EBM K5
- [41] Murray RB, Adler MW, Korczyn AD. The pupillary effects of opioids. *Life Sci* 1983; 33: 495–509
- [42] Palestine AG. Transient acute myopia resulting from isotretinoin (Accutane) therapy. *Ann Ophthalmol* 1984; 16: 660–662 EBM K6
- [43] Pallin O, Ericsson R. Ultrasound studies in a case of hygroton-induced myopia. *Acta Ophthalmol (Copenh)* 1965; 43: 692–696 EBM K6
-

-
- [44] Peacock JE, Herderson PD, Nimmo WS. Changes in pupil diameter after oral administration of codeine. *Br J Anaesth* 1988; 61: 598–600 EBM K4
- [45] Pek H, Wilhelm H. Einfluß von Dorzolamid auf Akkommodation und Pupillenreaktion? *Ophthalmologe* 2000; 97: 769–773 EBM K1
- [46] Sanford-Smith JH. Transient myopia after aspirin. *Br J Ophthalmol* 1974; 58: 698–700 EBM K6
- [47] Schwartz H, Apt L. Mydriatic effect of anticholinergic drugs used during reversal of nondepolarizing muscle relaxants. *Am J Ophthalmol* 1979; 88: 609–612
- [48] Segal A, Aisemberg A, Ducasse A. Quinine, myopie transitoire et glaucome par fermeture de l'angle. *Bull Soc Opt France* 1983; LXXXIII: 246–248 EBM K6
- [49] Seymor JF. Carbamazepine overdose. Feature of 33 cases. *Drug Saf* 1993; 8: 81–88 EBM K5
- [50] Stern JJK. Transient myopia in case of dermatitis treated with corticotropin. *Arch Ophthalmol* 1955; 54: 762 EBM K6
- [51] Szabadi E, Bradshaw CM. Autonomic pharmacology of α 2-adrenoceptors. *J Psychopharmacology* 1996; 10: 6–18
- [52] Teller J, Rasin M, Abraham FA. Accommodation insufficiency induced by glybenclamide. *Ann Ophthalmol* 1989; 21: 275–276 EBM K6
- [53] Thompson HS, Newsome DA, Loewenfeld IE. The fixed dilated pupil. Sudden iridoplegia or mydriatic drops? A simple diagnostic test. *Arch Ophthalmol* 1971; 86: 21–27
- [54] Vallersnes OM, Lund C, Duns AK et al. Epidemic of poisoning caused by scopolamine disguised as Rohypnol tablets. *Clin Toxicol (Phila)* 2009; 47: 889–893 EBM K5
- [55] Verdier DD, Kennerdell JS. Fixed dilated pupil resulting from transdermal scopolamine. *Am J Ophthalmol* 1982; 93: 803–804 EBM K6
- [56] Whitacre MM, Ellis PP. Outpatient sedation for ocular examination. *Surv Ophthalmol* 1984; 28: 643–652
- [57] Wilhelm B, Wilhelm H, Lüdtk H, et al. Pupillographic assessment in sleepiness in sleep-deprived healthy subjects. *Sleep* 1998; 21: 258–265 EBM K4
- [58] Wilhelm H. The pupil. *Curr Opin Neurol* 2008; 21: 36–42
- [59] Wisniewski M, Lukasik-Glebocka M, Anand JS. Acute topiramate overdose – clinical manifestations. *Clin Toxicol (Phila)* 2009; 47: 317–320 EBM K6
- [60] Yasuno E. Acute myopia associated with prochlorperazine (Compazine) therapy. *Am J Ophthalmol* 1962; 54: 793–796 EBM K6
- [61] Yüksel N, Güler C, Caglar Y et al. Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers. *Int Ophthalmol* 1992; 16: 337–342 EBM K1

Kap. 15

- [1] Abrams SM. Marrow aplasia following topical application of chloramphenicol eye ointment. *Arch Intern Med* 1980; 140: 576–577 EBM K6
- [2] Alm A, Widengard I. Latanoprost. Experience of 2-year treatment in Scandinavia. *Acta Ophthalmol Scand* 2000; 78: 71–76 EBM K1
- [3] Arranz Marquez E, Teus Guezala MA, Canseco Gonzalez F. Respirator effects of chronic therapy with latanoprost in patients with chronic obstructive pulmonary disease (COPD). *Arch Soc Esp Oftalmol* 2002; 77: 553–558 EBM K6
- [4] Bailey PL. Timolol and postoperative apnea in neonates and young infants. *Anesthesiology* 1984; 61: 622 EBM K6
- [5] Baldwin FJ, Morley AP. Intraoperative pulmonary oedema in a child following systemic absorption of phenylephrine eyedrops. *Br J Anaesth* 2002; 88: 440–442 EBM K6
- [6] Berlin RJ, Lee UT, Sampels JR et al. Ophthalmic drops causing coma in an infant. *J Pediatr* 2001; 138: 441–443 EBM K6
- [7] Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. *Eye* 2004; 18: 24–26 EBM K5
- [8] Bruckhausen D, Hasches J, Dardene MU. Veränderungen des Bronchialwiderstandes bei Asthmatikern nach Applikation von Pilocarpin in den Konjunktivalsack. *Dtsch Med Wochenschr* 1969; 68: 1003–1010 EBM K4
- [9] Carlsen JO, Zabriskie NA, Kwon YH et al. Apparent central nervous system depression in infants after the use of topical brimonidine. *Am J Ophthalmol* 1999; 128: 255–256 EBM K6

-
- [10] Coppens G, Stalmans I, Zeyen T et al. The safety and efficacy of glaucoma medication in the pediatric population. *J Pediatr Ophthalmol Strabismus* 2009; 46: 12–18
- [11] Demayo AP, Reidenberg MM. Gran mal seizure in a child 30 minutes after Cyclogyl (cyclopentolate hydrochloride) and 10% Neo-Syneprine (phenylephrine hydrochloride) eye drops were instilled. *Pediatrics* 2004; 113: e499–500 EBM K6
- [12] Diamond JP. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. *Drugs Aging* 1997; 11: 352–360
- [13] Doshi B, Sarkar S. Topical administration of chloramphenicol can induce acute hepatitis. *BMJ* 2009; 338: b1699 EBM K6
- [14] DuBiner H, Cooke D, Dirks M et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. *Surv Ophthalmol* 2001; 45 (Suppl. 4): 353–360 EBM K1
- [15] Erb C. Glaukom. In: Erb C, Schlote T, Hrsg. *Medikamentöse Augentherapie*. Stuttgart: Thieme Verlag; 2010
- [16] Epstein E, Kaufman I. Systemic pilocarpine toxicity from overdosage in treatment of an attack of angle closure glaucoma. *Am J Ophthalmol* 1965; 59: 109–110 EBM K6
- [17] Genvert GI, Cohen EJ, Donnenfeld ED et al. Erythema multiforme after use of topical sulfacetamide. *Am J Ophthalmol* 1985; 99: 465–468 EBM K6
- [18] Goldberg I, Moloney G, McCluskey P. Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications? *Med J Aust* 2008; 189: 356–357
- [19] Gottschalk HR, Stone OJ. Stevens-Johnson syndrome from ophthalmic sulfonamide. *Arch Dermatol* 1976; 112: 513–514 EBM K6
- [20] Hedner J, Everts B, Moller CS. Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation. *Arch Ophthalmol* 1999; 117: 1305–1309 EBM K1
- [21] Isenberg SJ, Abrams C, Hyman PE. Effect of cyclopentolate eyedrops on gastric secretory function in pre-term infants. *Ophthalmology* 1985; 92: 698–700 EBM K6
- [22] Jensen P, Edgren B, Hall L et al. Hemodynamic effects following ingestion of an imidazoline-containing product. *Pediatr Emerg Care* 1989; 5: 110–112 EBM K6
- [23] Katayama H, Yokoyama A, Fujino S et al. Near-death asthmatic reaction induced by disodium cromoglycate. *Intern Med* 1996; 35: 976–978 EBM K6
- [24] Kim JM, Stevenson CE, Methewson HS. Hypertensive reactions to phenylephrine eyedrops in patients with sympathetic denervation. *Am J Ophthalmol* 1978; 85: 862–868 EBM K5
- [25] Kluger N, Guillot B, Raison-Peyron N. Systemic contact dermatitis to dorzolamide eye drops. *Contact Dermatitis* 2008; 58: 167–168 EBM K6
- [26] Lai Becker M, Huntington N, Woof AD. Brimonidine tartrate poisoning in children: frequency, trends, and use of naloxone as an antidote. *Pediatrics* 2009; 123: e305–311 EBM K5
- [27] Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. *Am J Ophthalmol* 2002; 134: 749–760
- [28] Lazarov A, Amichai B. Skin reactions due to eye drops: report of two cases. *Cutis* 1996; 58: 363–364 EBM K6
- [29] Lim DL, Batilando M, Rajadurai VS. Transient paralytic ileus following the use of cyclopentolate-phenylephrine eye drops during screening for retinopathy of prematurity. *J Pediatr Child Health* 2003; 39: 318–320 EBM K6
- [30] Littmann L, Kempler P, Rohla M et al. Severe symptomatic atrioventricular block induced by pilocarpine eye drops. *Arch Intern Med* 1987; 147: 586–587 EBM K6
- [31] Mackie BS, Mackie LE. Systemic lupus erythematosus–dermatomyositis induced by sulfacetamide eye drops. *Australas J Dermatol* 1979; 20: 49–50 EBM K6
- [32] Marshall WF, Rosenthal P, Merritt RJ. Atropine therapy and paralytic ileus in an infant. *J Pediatr Gastroenterol Nutr* 1989; 9: 532–534 EBM K6
- [33] Marti V, Guindo J, Vallés E et al. Variant angina associated with latanoprost. *Med Clin (Barc)* 2005; 125: 238–239 EBM K6
- [34] McGhee CN, Anastas CN. Widespread ocular use of topical chloramphenicol: is there justifiable concern regarding idiosyncratic aplastic anaemia? *Br J Ophthalmol* 1996; 80: 182–184
- [35] Minish T, Herd A. Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report. *J Emerg Med* 2002; 22: 247–249 EBM K6

-
- [36] Mirshahi A, Kohnen T. Acute psychotic reaction caused by topical cyclopentolate use for cycloplegic refraction before refractive surgery: case report and review of the literature. *J Cataract Refract Surg* 2003; 29: 1026–1030 EBM K6
- [37] Mitra M, Chang B, James T. Exacerbation of angina associated with latanoprost. *BMJ* 2001; 323: 783 EBM K6
- [38] Mulhall A, de Louvois J, Hurley R. Chloramphenicol toxicity in neonates: its incidence and prevention. *Br Med J* 1983; 287: 1424–1427 EBM K5
- [39] Müskens RP, Wolfs RC, Wittman JC et al. Topical beta-blockers and mortality. *Ophthalmology* 2008; 115: 2037–2043
- [40] Mwanza JC. Cyclopentolate and grand mal seizure. *Bull Soc Belge Ophtalmol* 199; 273: 17–18 EBM K6
- [41] Newman DK, Jordan K. Generalised urtikaria induced by topical cyclopentolate. *Eye* 1996, 10: 750–760 EBM K6
- [42] Nordlund JR, Pasquale LR, Robin AL et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. *Arch Ophthalmol* 1995; 113: 77–83 EBM K1
- [43] Ott EZ, Mills MD, Arango S et al. A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years. *Arch Ophthalmol* 2005, 123: 1177–1186 EBM K1
- [44] Ozerdem U, Levi L, Cheng L et al. Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. *Am J Ophthalmol* 2000; 130: 240–241 EBM K6
- [45] Polachek J, Shvartzman P. Acute bronchial asthma associated with the administration of ophthalmic indomethacin. *Isr J Med Sci* 1996; 32: 1107–1109 EBM K6
- [46] Ramdas WD, van der Velde N, van der Cammen TF et al. Evaluation of risk of falls and orthostatic hypotension in older long-term topical beta-blocker users. *Graefes Arch Clin Exp Ophthalmol* 2009; 247: 1235–1241 EBM K5
- [47] Robertson D. Contraindication to the use of ocular phenylephrine in idiopathic orthostatic hypotension. *Am J Ophthalmol* 1979; 87: 819–822 EBM K5
- [48] Robin AL. Short-term effects of unilateral 1% apraclonidine therapy. *Arch Ophthalmol* 1988; 106: 912–915 EBM K1
- [49] Roters S, Aspacher F, Diestelhorst M. The influence of dexamethasone 0.1% eye drops on plasma cortisol and ACTH concentrations after cataract surgery. *Ophthalmologica* 1996; 210: 211–214 EBM K5
- [50] Sanso RS. Gastrointestinal spasm from low dosage pilocarpine. *Pe Med* 1980; 83: 24 EBM K6
- [51] Shelley WB, Shelley ED. Nonpigmenting fixed drug eruption as a distinctive reaction pattern: examples caused by sensitivity to pseudoephedrine hydrochloride and tetrahydrozoline. *J Am Acad Dermatol* 1987; 17: 403–407 EBM K6
- [52] Silverstone BZ, Marcus T. Hypoglycemia due to ophthalmic timolol in a diabetic. *Harefuah* 1990; 118: 693–694 EBM K6
- [53] Sitenga GL, Ing EB, Van Dellen RG et al. Asthma caused by topical application of ketorolac. *Ophthalmology* 1996; 103: 890–892 EBM K6
- [54] Sorensen SJ, Abel SR. Comparison of the ocular beta-blockers. *Ann Pharmacother* 1996; 30: 43–54
- [55] Strahlman E, Tipping R, Vogel R et al. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. *Arch Ophthalmol* 1995; 113: 1009–1016 EBM K1
- [56] Uchio E, Kadonosono K. Acute asthma attack caused by ophthalmic application of antiallergic agents. *Jpn J Ophthalmol* 2004; 48: 475–477 EBM K6
- [57] Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. *Surv Ophthalmol* 1993; 37: 435–456
- [58] Van der Spek AF. Cyanosis and cardiovascular depression in a neonate: complications of halothane anesthesia or phenylephrine eyedrops? *Can J Ophthalmol* 1988; 22: 37–39 EBM K6
- [59] Vander Zanden JA, Valuck RJ, Bunch CL et al. Systemic adverse effects of ophthalmic beta-blockers. *Ann Pharmacother* 2001; 35: 1633–1637
- [60] Vanhaesebrouck S, Cossey V, Cosaert K et al. Cardiorespiratory depression and hyperglycemia after unintentional ingestion of brimonidine in a neonate. *Eur J Ophthalmol* 2009; 19: 694–695 EBM K6
- [61] Velde TM, Kaser FE. Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient. *Arch Intern Med* 1983; 143: 1627 EBM K6
- [62] Veyrac G, Chiffolleau A, Cellierin L et al. Latanoprost (Xalatan) and a systemic respiratory effect? Apropos a case. *Therapy* 1999; 54: 494–496 EBM K6
- [63] Wesley RE, Blount WC, Arterberry IF. Pulmonary embolism in a diabetic patient after ocular 40% phenylephrine. *Ann Ophthalmol* 1981; 13: 311–313 EBM K6
- [64] Wright TM, Freedman SF. Exposure to topical apraclonidine in children with glaucoma. *J Glaucoma* 2009; 18: 395–398
-

- [65] Yüksel N, Güler C, Caglar Y et al. Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers. *Int Ophthalmol* 1992; 16: 337–342 EBM K1

Kap. 16

- [1] Ascaso FJ, Tiestos MT, Navales J et al. Fatal acute myocardial infarction after intravenous fluorescein angiography. *Retina* 1993; 13: 238–239 EBM K6
- [2] Asensio Sanchez VM, Corral Azor A, Garcia Pascual A. Verteporfin and photosensitivity in diabetic. *Arch Soc Esp Oftalmol* 2003; 78: 277–279 EBM K6
- [3] Devogelaer JP, Goemaere S, Boonen S et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. *Osteoporos Int* 2006; 17: 8–19
- [4] Doshi AB, Moshfeghi DM, Jack RL. Anaphylactoid reaction after verteporfin therapy. *Am J Ophthalmol* 2005; 140: 936–937 EBM K6
- [5] Filippi LO, Bagnoli F, Margollicci M et al. Pathogenic mechanism, prophylaxis, and therapy of symptomatic acidosis induced by acetazolamide. *J Investig Med* 2002; 50: 125–132 EBM K6
- [6] Hitosogu M, Omura K, Yokoyama T et al. An autopsy case of fatal anaphylactic shock following fluorescein angiography: a case report. *Med Sci Law* 2004; 44: 264–265 EBM K6
- [7] Hope-Ross M, Yannuzzi LA, Gragoudas ES et al. Adverse reactions due to indocyanine green. *Ophthalmology* 1994; 101: 529–533 EBM K4
- [8] Karhunen U, Raitta C, Kala R. Adverse reactions to fluorescein angiography. *Acta Ophthalmol* 1986; 64: 282–286 EBM K5
- [9] Kwan AS, Barry C, McAllister IL et al. Fluorescein angiography and adverse drug reactions revisited: the Lions Eye experience. *Clin Experiment Ophthalmol* 2006; 34: 33–38 EBM K5
- [10] Kwiterovich KA, Maguire MG, Murphy RP et al. Frequency of adverse systemic reactions after fluorescein angiography. Results of a prospective study. *Ophthalmology* 1991; 98: 1139–1142 EBM K4
- [11] Olsen TW, Lim JI, Capone A Jr et al. Anaphylactic shock following indocyanine green angiography. *Arch Ophthalmol* 1996; 114: 97 EBM K6
- [12] McAllister RG Jr. Hypertensive crisis and myocardial infarction after fluorescein angiography. *South Med J* 1981; 74: 508–509 EBM K6
- [13] Schnurrbusch UE, Jochmann C, Einbock W et al. Complications after photodynamic therapy. *Arch Ophthalmol* 2005; 123: 1347–1350 EBM K5
- [14] Shahid H, Salmon JF. Anaphylactic response to topical fluorescein 2% eye drops: a case report. *J Med Case Reports* 2010; 4: 27 EBM K6
- [15] Torres MJ, Canto G. Hypersensitivity reactions to corticosteroids. *Curr Opin Allergy Clin Immunol* 2010; 10: 273–279
- [16] Vermaat H, Kirtschig G. Prevention and treatment of glucocorticoid-induced osteoporosis in daily dermatologic practice. *Int J Dermatol* 2008; 47: 737–742
- [17] Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularisation due to age-related macular degeneration and other causes: update. *Retina* 2005; 25: 119–134
- [18] Wolf S, Arend O, Schulte K et al. Severe anaphylactic reaction after indocyanine green fluorescence angiography. *Am J Ophthalmol* 1992; 114: 638–639 EBM K6